



## Konstantinos Efthymiadis

**Passport:** AT6115262 | **Work permit:** Greek, British | **Date of birth:** 02/07/1982 |

**Place of birth:** Thessaloniki, Greece | **Nationality:** Greek | **Phone:** (+30) 6974000978 (Mobile) |

**Email:** [efthymiadis@gmail.com](mailto:efthymiadis@gmail.com) | **Email:** [kefthymiadis@auth.gr](mailto:kefthymiadis@auth.gr) |

**Address:** Patriarchou Ioakeim 7, 54622, Thessaloniki, Greece (Home)

### ● ABOUT MYSELF

Medical Oncologist based in Greece

- Specializing in Lung Cancer, Sarcoma, and Early Phase Clinical Trials
- License to practise in Greece and the UK
- A.I. enthusiast

### ● WORK EXPERIENCE

 **UNIVERSITY COLLEGE LONDON HOSPITALS NHS FOUNDATION TRUST** – LONDON, UNITED KINGDOM

**Business or Sector** Human health and social work activities |

**Department** University College London Hospitals NHS Foundation Trust Oncology Service |

**Address** 250 Euston Road, 1st Floor Central, NW1 2PG, London, United Kingdom |

**Website** <https://www.uclh.nhs.uk/our-services/find-service/cancer-services>

**CONSULTANT MEDICAL ONCOLOGIST** – 27/09/2023 – 31/12/2024

Fixed-term, full-time employment contract/ 40 hours per week.

Main activities and responsibilities:

- Responsible for the care of patients with sarcoma from 25 years, including delivery of systemic anti-cancer therapy for outpatient clinic, as well as follow up patient consultations,
- Participation in the new patient allocation rota for newly diagnosed adult bone and soft tissue sarcoma patients requiring curative or palliative systemic anti-cancer treatment,
- Responsible for the completion of the monthly 30-day mortality and morbidity clinical audit for patients who die within 30 days after receiving systemic anti-cancer treatment
- Participation in consultant-led supervision of ward patients
- Supervision of junior doctors and trainees,
- Participation in the Consultants' on-call rota,
- Participation in 4 weekly MDT meetings,
- Participation in the Oncology Audit and Governance meetings,
- Participation in 8 Clinical Trials of the Department as a sub-investigator.

 **UNIVERSITY COLLEGE LONDON HOSPITALS NHS FOUNDATION TRUST/ CLINICAL RESEARCH FACILITY** – LONDON, UNITED KINGDOM

**Business or Sector** Human health and social work activities |

**Department** UCLH NHS Foundation Trust- NIHR/ Clinical Research Facility |

**Address** 170 Tottenham Court Road, 4th Floor London, W1T 7HA, London, United Kingdom |

**Website** <https://www.uclhospitals.brc.nihr.ac.uk/clinical-research-facility>

**CLINICAL RESEARCH FELLOW IN EARLY PHASE CANCER TRIALS** – 25/01/2023 – 26/09/2024

Fixed-term, full-time employment contract/ 40 hours per week.

Main activities and responsibilities:

- Responsible for the care of patients attending the Early Phase Cancer Trial Clinical Research Facility of UCLH NHS Foundation Trust,
- Responsible for patient screening, and consenting, as well as prescribing systemic anti-cancer therapy, including first-in-human investigational pharmaceutical agents within active early phase clinical trials,

- Participating in 5 weekly MDTs,
- Supervising junior doctors and trainees,
- Participation in 34 Clinical Trials of the Department as a sub-investigator.

 **PAPAGEORGIOU GENERAL HOSPITAL** – THESSALONIKI, GREECE

**Business or Sector** Human health and social work activities |

**Department** Medical Oncology Department, Aristotle University of Thessaloniki |

**Address** Periferiaki Odos, Nea Efkarpia, 56403, Thessaloniki, Greece | **Website** <https://www.papageorgiou-hospital.gr/?lang=en>

### **CONSULTANT MEDICAL ONCOLOGIST** – 26/08/2019 – 25/08/2022

Fixed-term, full-time employment contract/ 40 hours per week.

Main activities and responsibilities:

- Prescribing and supervising prescription of chemotherapy and immunotherapy for patients across all tumor types at the day unit clinic three days per week,
- Offering consultant services for patients on follow-up once a week,
- Supervising ward rounds and providing guidance to trainees on alternate weeks,
- Participating in the Consultants' on-call rota,
- Participating in the MDTs held at the Department on a rotational schedule with the other consultants,
- Providing teaching lectures for undergraduate students and postgraduate students,
- Participating in 14 Clinical Trials of the Department as a sub-investigator.

 **PAPAGEORGIOU GENERAL HOSPITAL** – THESSALONIKI, GREECE

**Business or Sector** Human health and social work activities |

**Department** Medical Oncology Department, Aristotle University of Thessaloniki |

**Address** Periferiaki Odos, Nea Efkarpia, 56403, Thessaloniki, Greece | **Website** <https://www.papageorgiou-hospital.gr/?lang=en>

### **RESIDENT DOCTOR IN MEDICAL ONCOLOGY** – 22/09/2015 – 25/08/2019

Fixed-term, full-time employment contract/ 40 hours per week. Training in Medical Oncology.

My duties as a trainee in Medical Oncology included active participation in all activities of the Department:

- ward rounds,
- outpatient day-clinic and follow-up patients,
- Acute Oncology Service on-call duties seven days per month,
- participating in the MDTs as an observer,
- providing presentations for the Department's scientific program and Journal Club,
- participating in the Department's research work.

After specialty training completion on 22/09/2018 and successful participation in the National Board Certified Examination on 16 October 16 2018, i acquired the title of Medical Oncologist and continued working for the same Department with a contract extension until 25 August 2019.

 **THEAGENEIO CANCER HOSPITAL** – THESSALONIKI, GREECE

**Business or Sector** Human health and social work activities |

**Department** 1st Medical Oncology Department, Theageneio Cancer Hospital |

**Address** Alexandrou Symeonidi 2, 54639, Thessaloniki, Greece | **Website** <https://theageneio.gov.gr/el/>

### **RESIDENT DOCTOR IN INTERNAL MEDICINE** – 08/05/2012 – 09/07/2015

Fixed-term, full-time employment contract/ 40 hours per week. Training in Internal Medicine, including 6 months in Haematology.

My duties included active participation in all activities of the Department including:

- Acute Service for Cancer Patients,
- ward rounds,
- outpatient day-clinic and follow-up patients,
- participating in the MDTs as an observer,
- providing presentations for the Department's scientific program and Journal Club,
- participating in the Department's research work.

 **FLORINA GENERAL HOSPITAL** – FLORINA, GREECE

**Business or Sector** Human health and social work activities | **Address** Egnatias 9, 53100, Florina, Greece |

**Website** <https://florinahospital.gr/>

## **RURAL SERVICE DOCTOR** – 01/02/2012 – 08/05/2012

Fixed-term, full-time employment contract/ 40 hours per week.

I worked as a Rural General Practitioner at the Health Centre of Amyntaio and the village of Antigoneia, as well as in the Department of

Cardiology at the General Hospital of Florina, Greece, participating in the Cardiology Department emergency on-call rota and ward rounds.

I stopped in order to start my official training in Internal Medicine at Theageneio Cancer Hospital.

 **GREEK ARMY** – GREECE

## **MILITARY DOCTOR, RESERVE SECOND LIEUTENANT** – 01/02/2011 – 01/11/2011

Served compulsory Military Service as a Military Doctor in the Greek Army. Military service as Reserve Second Lieutenant.

I offered my services at 5 military units of the Greek Army:

- 1) Health Services Army Recruit Center (as recruit medical screening physician),
- 2) 108 Self-propelled Field Middle Artillery Squadron (as field exercise and squadron physician),
- 3) 2nd Alpine Rangers Squadron-Greek Army Special Forces (as field exercise doctor, squadron physician and Minefield Clearance Unit doctor),
- 4) 194 Multiple Launch Rocket System Squadron (as field exercise and squadron physician),
- 5) 162 Self-propelled Field Heavy Artillery Squadron (as squadron & field exercise physician and responsible for recruit health management and screening).

## ● **EDUCATION AND TRAINING**

CURRENT Thessaloniki, Greece

**PH.D. STUDENT** Aristotle University of Thessaloniki, School of Medicine

**Address** University Campus, 54124, Thessaloniki, Greece | **Website** <https://www.auth.gr/en/school/med-en/> |

**Thesis** Genomic alterations as disease prognostic biomarkers in patients with NSCLC

30/09/2004 – 12/07/2010 Thessaloniki, Greece

**MEDICAL DEGREE/ PTYCHIO IATRIKES (MBBS EQUIVALENT)** Aristotle University of Thessaloniki, School of Medicine

**Address** University Campus, 54124, Thessaloniki, Greece | **Website** <https://www.auth.gr/en/school/med-en/> |

**Final grade** 7.98 (eight)- "Very Good"

01/09/2007 – 10/11/2009 Thessaloniki, Greece

**M.SC. IN MEDICAL RESEARCH METHODOLOGY** Aristotle University of Thessaloniki, School of Medicine

My graduation thesis was carried out in collaboration with the Histology-Embryology University Laboratory and the 1st University Department of Obstetrics and Gynecology of the Aristotle University Medical School, with its subject being: "Sex ratio at fetal death and fetus with congenital abnormalities". Thesis grade: 10 (excellent).

**Address** University Campus, 54124, Thessaloniki, Greece | **Website** <https://mrm.med.auth.gr/> | **Final grade** 9.53 - "Excellent" |

**Thesis** Sex ratio at fetal death and fetus with congenital abnormalities

01/09/2000 – 29/09/2004 Larissa, Greece

**B.SC. DEGREE/ PTYCHIO IN BIOCHEMISTRY – BIOTECHNOLOGY** Department of Biochemistry and Biotechnology, School of Health Sciences, University of Thessaly

My graduation thesis was submitted to the Department of Agricultural Sciences at the Catholic University of the Sacred Heart of Milan, with the title "The effect of fruit epicuticular waxes of the species *Malus communis* (apples), *Fragaria vesca* (strawberries) and *Citrus* (grapefruits) on the photodegradation rate of the insecticide- acaricide Chlorpyrifos-

methyl and the fungicide Procymidone” as part of the Italian Ministry of Health Nutrition Research Program. Thesis grade: 10 (excellent).

**Address** Biopolis Campus, 415 00, Larissa, Greece | **Website** <https://bio.uth.gr/en/home/> | **Final grade** 7.30 - "Very Good" |

**Thesis** The effect of fruit epicuticular waxes of the species Malus commuxis (apples), Fragaria vesca (strawberries) and Citrus (grapefruits) on the photodegradation rate of the insecticide- acaricide Chlorpyrifos-methyl and the fungicide Procymidone

1988 – 2000 Thessaloniki, Greece

**ELEMENTARY AND HIGH SCHOOL EDUCATION GRADUATE** "Korais" Private School

## ● LANGUAGE SKILLS

Mother tongue(s): **GREEK**

Other language(s):

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken production	Spoken interaction	
<b>ENGLISH</b>	C2	C2	C2	C2	C1
<b>ITALIAN</b>	B1	B1	A2	B1	A2
<b>FRENCH</b>	A2	A2	A1	A2	A1

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user

## ● POSTGRADUATE MEDICAL QUALIFICATIONS

01/09/2022 – CURRENT

**General Medical Council registration on the Specialist Register with license to practice the specialty of Medical Oncology**

General Medical Council registration. Reference number 8006745 with a license to practice and specialist registration entry for the specialty of Medical Oncology

15/11/2018 – CURRENT

**Greek License to practice the qualification of Medical Specialty in “Medical Oncology” (CCST equivalent)**

License to practice the qualification of Medical Specialty in “Medical Oncology” (CCST equivalent) Registration Number: Ref DDYKM/M.E.TH.470084 (26999), Region of Central Macedonia, General Directorate of Public Health and Social Welfare, Directorate of Public Health and Social Welfare, Metropolitan Unit of Thessaloniki, Department of Public Health, Greece

20/10/2018 – CURRENT

**ESMO Examination Successful Participation Certificate**

ESMO Examination Successful Participation Certificate, score:73, Munich, Germany

16/10/2018 – 16/10/2018

**Successful participation in CCST Examination for the medical specialty of Medical Oncology**

Successful participation in CCST Examination for the medical specialty of Medical Oncology, Thessaloniki, Greece

25/11/2010 – CURRENT

**Greek License to Practice Medicine**

License to Practice Medicine, Registration No: Γ1/29637 Prefectural Authority of Thessaloniki, Greece

## ● **INTERNATIONAL POSTGRADUATE TRAINING**

---

08/10/2023 – 08/10/2023

**Good Clinical Practice (GCP) Refresher e-Learning, NIHR- National Institute for Health and Care Research U.K. Version May 2022**

---

Pain and Palliative Care Management Training at Institut Curie, 24-28 February 2020, Paris, France

08/10/2023 – 08/10/2023

**Introduction to Good Clinical Practice (GCP) e-Learning, NIHR- National Institute for Health and Care Research U.K.**

---

Pain and Palliative Care Management Workshop by Institut Curie, 17-18 October 2019, Thessaloniki, Greece

08/10/2023 – 08/10/2023

**Introduction to GCP – IMP Management, NIHR- National Institute for Health and Care Research U.K.**

---

Ovarian Cancer Clinical Observation Program, Policlinico Universitario Agostino Gemelli, 8-9 July 2019, Rome, Italy

10/10/2022 – 10/10/2022

**ICH E6 GCP Investigator Training Version 2.1**

---

ESSO Advanced Course on Surgical and Medical Management of Melanoma, 10-13 October 2013, Santorini, Greece

07/12/2020 – 07/12/2020

**ICH E6 GCP Investigator Training Version 2.1**

---

Winter School: “The Multidisciplinary Therapeutic Approach of Rare Tumors”, 28 February-03 March 2013, Volos, Greece

24/02/2020 – 28/02/2020

**Pain and Palliative Care Management Training at Institut Curie**

---

Preceptorship in Clinical and Translational Cancer Research, 12-15 November 2012, Medical School, University of Crete, Greece

09/01/2020 – 09/01/2020

**ICH GCP Investigator Training Version 2, Apr-2018**

---

17/10/2019 – 18/10/2019

**Pain and Palliative Care Management Workshop by Institut Curie**

---

08/07/2019 – 09/07/2019

**Ovarian Cancer Clinical Observation Program, Policlinico Universitario Agostino Gemelli**

---

12/10/2018 – 12/10/2018

**ESMO E-Learning program successful participation: Handbook of Cancer in the Senior Patient 2nd Edition**

---

12/10/2018 – 12/10/2018

**ESMO E-Learning program successful participation: Handbook of Cancer Diagnosis and Treatment Evaluation**

---

03/10/2018 – 03/10/2018

**ESMO E-Learning program successful participation: Overview of the Diagnosis and Treatment of GI NETs**

---

10/10/2013 – 13/10/2013

**ESSO Advanced Course on Surgical and Medical Management of Melanoma**

---

28/02/2013 – 03/03/2013

**Winter School: “The Multidisciplinary Therapeutic Approach of Rare Tumors”**

---

● **NATIONAL POSTGRADUATE TRAINING**

---

21/02/2018 – 25/02/2018

**3rd Masterclass on GI Cancers, Organization: EM-KAPES**

---

3rd Masterclass on GI Cancers, Organization: EM-KAPES, 21-25 February 2018, Delphi, Greece

15/03/2017 – 19/03/2017

**2nd Masterclass on GI Cancers, Organization: EM-KAPES**

---

2nd Masterclass on GI Cancers, Organization: EM-KAPES, 15-19 March 2017, Volos, Greece

2014 – 2015

**Hellenic Oncology Academy Courses (EAKO), Hellenic Society of Medical Oncology (HeSMO), 4th Cycle**

---

Hellenic Oncology Academy Courses (EAKO), Hellenic Society of Medical Oncology (HeSMO), 4th Cycle:

7th Session-Melanoma, Sarcoma & CNS tumors, 18-19 September 2015, Athens, Greece.

6th Session-Breast Cancer, 05-06 June 2015, Athens, Greece.

5th Session-Gynecologic Cancer, 13-14 March 2015, Athens, Greece.

4th Session-Malignant Neoplasms of the Urogenital System, 28-30 November 2014, Athens, Greece.

3rd Session-Malignant Neoplasms of the GI system, 03-05 October 2014, Athens, Greece.

2nd Session-Thoracic & Mediastinal Neoplasms and Head & Neck Cancer, 23-24 May 2014, Athens, Greece.

1st Session-Biology of Cancer, Basic Principles of Oncology, 14-15 February 2014, Athens, Greece.

● **TEACHING EXPERIENCE**

---

2018 – CURRENT

**Undergraduate MD Program of Studies of the Medical School of the Aristotle University of Thessaloniki, Spring semester optional lesson "Medical Oncology"**

---

Lectures:

"Cancer Epidemiology- Prevention" (2018- ongoing)

"Oncogenes" (2020- ongoing)

"Chemotherapy Toxicity" (2021- 2022, 2022- 2023)

2018 – CURRENT

**M.Sc. Program of Studies "Health and Environmental Factors" of the Medical School of the Aristotle University of Thessaloniki, Spring semester compulsory lesson "Infectious, Mutagenic, Toxic Factors- Methodologies for detecting mutagenic substances/ Teratogenesis, Carcinogenesis and Environment".**

---

Lectures:

"Cancer Epidemiology"

"Environment and Cancer"

2020 – CURRENT

**M.Sc. Program of Studies "Stem Cells and Regenerative Medicine" of the Medical School of the Aristotle University of Thessaloniki, Spring semester compulsory lesson "Stem Cells and Degenerative Diseases".**

---

Lecture:

"Cancer Stem Cells"

2021 – CURRENT

**Particle Therapy Masterclass, CERN- Conseil Européen pour la Recherche Nucléaire, GSI - Helmholtzzentrum für Schwerionenforschung GmbH, Aristotle University of Thessaloniki, National Center for Scientific Research "Demokritos"**

---

Lecture:

"Understanding Cancer, Prevention and Treatment"

07/02/2024 – 09/02/2025

## 10th Cycle of Studies of the Hellenic Academy of Oncology (EAKO)

---

2nd Educational Seminar: "Sarcoma, Melanoma, CNS Tumours, NETs, Rare tumours", 7-9 February 2025, Athens, Greece.

Lecture:

"GIST- Diagnosis, molecular alterations, and treatment approach"

2021 – 2022

## Undergraduate Medicine Degree Program of Studies of the Medical School of the Aristotle University of Thessaloniki, 5th Year Winter semester compulsory lesson "Internal Medicine"

---

Trainer in Patient Ward Rounds for the 5th Year Undergraduate Medical.

Lectures:

"Hypercalcemia- hypocalcemia"

"Lung Cancer"

06/11/2021 – 06/11/2021

## Greek Breast Surgery Society, Webinars Online Seminars, Fall- Winter 2021. 3rd Webinar "Neoadjuvant therapy in breast cancer"

---

Lecture:

"Neoadjuvant endocrine therapy. Update". Section: Special issues on neoadjuvant therapy.

10/02/2021 – 10/02/2021

## Postgraduate Lessons of the Northern Greece Surgical Society, 5th lesson: "Definitive Surgical Treatment of Colon Adenocarcinoma"

---

Lecture:

"What is Total Mesocolic Excision, what is its Place on Current Total Surgical Treatment of Colon Adenocarcinoma? The view of the Medical Oncologist"

17/04/2018 – 17/04/2018

## Postgraduate Orthopedic Lessons of the Medical Association of Thessaloniki 2018

---

Lecture:

"Management of Musculoskeletal Tumor Patients, Presentation of 4 Cases"

## ● PUBLICATIONS

---

2025

### [Efficacy of tocilizumab in severe COVID-19 infection: a retrospective observational study](#)

---

Sarigianni M, Efthymiadis K et al. Efficacy of tocilizumab in severe COVID-19 infection: a retrospective observational study. Aristotle Biomedical Journal. 2025; 7(1). doi: <https://doi.org/10.26262/abj.v7i1.10416>

**Authors:** Sarigianni M, Efthymiadis K, Toutziari E, Fantakis A, Moumtzi D, Theocharis K, Kritikos V, Trakatelli C-M, Kostis V. | **Journal Name:** Aristotle Biomedical Journal | **Volume, Issue and Pages:** Volume 7, Number 1

2024

### [A phase 2, single arm, multi-center trial evaluating the efficacy of afatinib as first line or later line treatment in advanced chordoma](#)

---

Lipplaa A, et al. A phase 2, single arm, multi-center trial evaluating the efficacy of afatinib as first line or later line treatment in advanced chordoma. JCO. 2024; 42(16). doi: [https://doi.org/10.1200/JCO.2024.42.16\\_suppl.11517](https://doi.org/10.1200/JCO.2024.42.16_suppl.11517)

**Authors:** Lipplaa A, Strauss SJ, Stacchiotti S, Kayani I, Efthymiadis K, Frezza AM, Meershoek-Klein Kranenbarg E, Sommer J, Flanagan A, Gelderblom H. | **Journal Name:** Journal of Clinical Oncology/ ASCO 2024 | **Volume, Issue and Pages:** Volume 42, Number 16

2024

### [Artificial intelligence-assisted evaluation of cardiac function by oncology staff in chemotherapy patients](#)

---

Papadopoulou SL et al. Artificial intelligence-assisted evaluation of cardiac function by oncology staff in chemotherapy patients. European Heart Journal - Digital Health. 2024 Volume 5, Issue 3, Pages 278–287, <https://doi.org/10.1093/ehjdh/ztae017>



**Authors:** Papadopoulou SL, Dionysopoulos D, Mentesidou V, Loga K, Michalopoulou S, Koukoutzeli C, Efthymiadis K, Kantartzi V, Timotheadou E, Styliadis I, Nihoyannopoulos P, Sachpekidis V. | **Journal Name:** European Heart Journal - Digital Health | **Volume, Issue and Pages:** Volume 5, Issue 3, Pages 278-287

2023

### [1312MO Combining the antigen-presenting cell activator eftilagimod alpha \(soluble {LAG}-3\) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma \(NSCLC\) cohort of TACTI-002 \(phase II\)](#)

---

Carcereny E et al. Combining the antigen-presenting cell activator eftilagimod alpha (soluble {LAG}-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma cohort of TACTI-002 (phase II). Ann Onc. 2023; 34 S754.

**Authors:** Carcereny E, Felip E, Majem M, Doger de Spéville B, Clay TD, Bondarenko I, Peguero J, Cobo Dols M, Forster MD, Ursol G, Kalinka E, Garcia Ledo GM, Vila Martinez L, Iams W, Krebs MG, Kefas J, Efthymiadis K, Perera S, Mueller C, Triebel F. | **Journal Name:** Annals of Oncology/ ESMO 2023 | **Volume, Issue and Pages:** Volume 34, Supplement 2, S754

2023

### [Use of artificial intelligence for the automatic assessment of left ventricular ejection fraction by oncology staff in chemotherapy patients](#)

---

Papadopoulou SL et al. Use of artificial intelligence for the automatic assessment of left ventricular ejection fraction by oncology staff in chemotherapy patients. European Heart Journal - Cardiovascular Imaging. 2023; 24 Sup\_1. doi: jead119.144

**Authors:** Papadopoulou SL, Dionysopoulos D, Mentesidou V, Loga K, Michalopoulou S, Koukoutzeli C, Efthymiadis K, Kantartzi V, Styliadis I, Nihoyannopoulos P, Sachpekidis V. | **Journal Name:** European Heart Journal - Cardiovascular Imaging/ EACVI 2023 | **Volume, Issue and Pages:** Volume 24, Issue Supplement 1

2023

### [A retrospective multicentric cohort study of checkpoint inhibitors-induced pruritus with focus on management](#)

---

Papageorgiou C, Lazaridou E, Lallas K, et al. A retrospective multicentric cohort study of checkpoint inhibitors-induced pruritus with focus on management. Photodermatol Photoimmunol Photomed. 2023; 39: 506-511. doi:10.1111/phpp.12892

**Authors:** Papageorgiou C, Lazaridou E, Lallas K, Papaioannou K, Nikolaou V, Mateeva V, Efthymiadis K, Koukoutzeli C, Loga K, Sogka E, Karamitrousis E, Lazaridis G, Dionysopoulos D, Lallas A, Christina Kemanetzi C, Fotiadou C, Timotheadou E, Apalla E. | **Journal Name:** Photodermatology, Photoimmunology and Photomedicine | **Volume, Issue and Pages:** Volume 39, Issue 5, Pages 506-511

2023

### [Investigating Predictive Factors of Dysphagia and Treatment Prolongation in Patients with Oral Cavity or Oropharyngeal Cancer Receiving Radiation Therapy Concurrently with Chemotherapy](#)

---

Alexidis P et al. Investigating Predictive Factors of Dysphagia and Treatment Prolongation in Patients with Oral Cavity or Oropharyngeal Cancer Receiving Radiation Therapy Concurrently with Chemotherapy. Curr. Oncol. 2023, 30(5), 5168-5178

**Authors:** Alexidis P, Kolias P, Mentesidou V, Topalidou M, Kamperis E, Giannouzakos V, Efthymiadis K, Bangeas P, Timotheadou E. | **Journal Name:** Current Oncology | **Volume, Issue and Pages:** Volume 30, Issue 5, Pages 5168-5178

2023

### [Narrative Review of Drug-Associated Nail Toxicities in Oncologic Patients](#)

---

Emvalomati A, Oflidou V, Papageorgiou C, et al. Narrative Review of Drug-Associated Nail Toxicities in Oncologic Patients. Dermatol Pract Concept. 2023;13(1):e2023064. doi:10.5826/dpc.1301a64

**Authors:** Emvalomati A, Oflidou V, Papageorgiou C, Kemanetzi C, Giannouli M, Kalloniati E, Efthymiadis K, Koukoutzeli C, Timotheadou E, Trigoni A, Patsatsi A, Lazaridou E, Apalla Z, Trakatelli M. | **Journal Name:** Dermatology Practical & Conceptual | **Volume, Issue and Pages:** Volume 13, Issue 1

2023

### [Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry](#)

---



Mountzios G et al. Molecular Epidemiology and Treatment Patterns of Patients With EGFR Exon 20-Mutant NSCLC in the Precision Oncology Era: The European EXOTIC Registry. JTO Clin Rep Res. 2023; 4(1). <https://doi.org/10.1016/j.jtocrr.2022.100433>.

**Authors:** Mountzios G, Planchard D et al. | **Journal Name:** Journal of Thoracic Oncology Clinical and Research Reports | **Volume, Issue and Pages:** Vol.4, Issue 1

2022

### [Investigating factors associated to dysphagia and need for percutaneous endoscopic gastrostomy in patients with head and neck cancer receiving radiation therapy](#)

Alexidis P, Bangeas P, Efthymiadis K, et al. Investigating factors associated to dysphagia and need for percutaneous endoscopic gastrostomy in patients with head and neck cancer receiving radiation therapy. J Cancer 2022; 13(5): 1523-1529.

**Authors:** Alexidis P, Bangeas P, Efthymiadis K, Drevelegkas K, Kolias P. | **Journal Name:** Journal of Cancer | **Volume, Issue and Pages:** Volume 13, Issue 5, Pages 1523-1529

2022

### [Role of minimally invasive surgery in the treatment of gallbladder metastatic melanoma. A review of the literature and a case report](#)

Bangeas PI, Bekiaridou A, Tsolakidis A, Efthymiadis KG et al. Role of minimally invasive surgery in the treatment of gallbladder metastatic melanoma. A review of the literature and a case report. Cancer Rep (Hoboken). 2022 Jul; 5(7):e1549.

**Authors:** Bangeas PI, Bekiaridou A, Tsolakidis A, Efthymiadis KG, Drevelegkas K, Giakoustidis D, Giakoustidis A, Alexidis P, Papadopoulos VN. | **Journal Name:** Cancer Reports (Hoboken) | **Volume, Issue and Pages:** Vol.5, Issue 7

2021

### [Multifocal low-grade astrocytoma successfully treated with volumetric modulated arc therapy and concurrent temozolomide](#)

Kamperis E, Dionysopoulos D, Efthymiadis K, et al. Multifocal low-grade astrocytoma successfully treated with volumetric modulated arc therapy and concurrent temozolomide. J Cancer Prev Curr Res. 2021;12(6):171-174. DOI: 10.15406/jcpcr.2021.12.00475

**Authors:** Kamperis E, Dionysopoulos D, Efthymiadis K, et al. | **Journal Name:** Journal of Cancer Prevention & Current Research | **Volume, Issue and Pages:** Vol.12, Issue 6, Pages 171-174

2021

### [Metastatic High-grade Ovarian Sarcoma: Complete Response with Trabectedin in a Haemodialyzed Patient. A Case Report and Review of the Literature](#)

Efthymiadis K et al. (2021). Metastatic High-grade Ovarian Sarcoma: Complete Response with Trabectedin in a Haemodialyzed Patient. A Case Report and Review of the Literature. New Frontiers in Medicine and Medical Research Vol. 12, 113-127.

**Authors:** Efthymiadis K, Adamidis C, Koukoutzeli C, Tzelepi V, Timotheadou E. | **Journal Name:** New Frontiers in Medicine and Medical Research | **Volume, Issue and Pages:** Vol.12, Pages 113-127

2019

### [Complete Response after Long-Term 2nd Line Treatment with Trabectedin in a Hemodialyzed Patient with Metastatic High-Grade Ovarian Sarcoma, Case Report and Short Review](#)

Efthymiadis K et al. Complete Response after Long-Term 2nd Line Treatment with Trabectedin in a Hemodialyzed Patient with Metastatic High-Grade Ovarian Sarcoma, Case Report and Short Review. Arch Clin Med Case Rep. 2019;3(6): 591-599.

**Authors:** Efthymiadis K, Adamidis C, Koukoutzeli C, Tzelepi V, Timotheadou E. | **Journal Name:** Archives of Clinical and Medical Case Reports | **Volume, Issue and Pages:** Vol.3, Issue 6, Pages 591-599

2011

### [The sex ratio of fetal deaths and its potential relation with the decline of sex ratio at birth in Greece](#)

Miliaras D, Efthymiadis K, Meditskou S. The sex ratio of fetal deaths and its potential relation with the decline of sex ratio at birth in Greece. Aristotle University Medical Journal, Vol. 38, Issue 3, October 2011.

**Authors:** Miliaras D, Efthymiadis K, Meditskou S. | **Journal Name:** Aristotle University Medical Journal | **Volume, Issue and Pages:** Vol.38, Issue 3

## ● ABSTRACTS AND POSTERS IN INTERNATIONAL CONFERENCES

---

05/03/2024 – 06/03/2024

### **Evaluating Access and Benefits of Free of Charge (FOC) schemes for Sarcoma Patients at a Tertiary Care Centre**

---

Geoghegan C., Morrow M., Efthymiadis K., Wood G., Windsor R., Strauss S. Evaluating Access and Benefits of Free of Charge (FOC) schemes for Sarcoma Patients at a Tertiary Care Centre. British Sarcoma Group Annual Conference, 5-6 March 2025, Newcastle, United Kingdom.

05/03/2025 – 06/03/2025

### **Change Proposal for Initiating Patient-Initiated Follow-Up – Desmoid Fibromatosis**

---

Barradas da Silva A., Ellis K., Palmer Makowski A., Efthymiadis K., Montemurro M., Karavasilis V. Change Proposal for Initiating Patient-Initiated Follow-Up – Desmoid Fibromatosis. British Sarcoma Group Annual Conference, 5-6 March 2025, Newcastle, United Kingdom.

13/11/2024 – 16/11/2024

### **P23 Metastatic alveolar soft part sarcoma: Pregnancy- related worsening and spontaneous exceptional remission postpartum- A case report**

---

Orosco Ttamina AL, Pozas J, Efthymiadis K, Jones RL, Strauss SJ. P23 Metastatic alveolar soft part sarcoma: Pregnancy-related worsening and spontaneous exceptional remission postpartum- A case report. CTOS Annual Meeting, 13-16 November 2024, San Diego, USA.

30/05/2024 – 03/06/2024

### **A phase 2, single arm, European multi-center trial evaluating the efficacy of afatinib as first line or later line treatment in advanced chordoma**

---

Lipplaa A, Strauss SJ, Stacchiotti S, Kayani I, Efthymiadis K, Frezza AM, Meershoek-Klein Kranenbarg E, Sommer J, Flanagan A, Gelderblom H. A phase 2, single arm, European multi-center trial evaluating the efficacy of afatinib as first line or later line treatment in advanced chordoma. ASCO Annual Meeting, 30 May-3 June 2024, Chicago, USA.

27/02/2024 – 28/02/2024

### **Exceptional disease response with the MDM2 inhibitor, Brigimadlin in a patient with multiply-treated MDM2 amplified metastatic intimal sarcoma of the heart**

---

Efthymiadis K., Geoghegan C., Barradas da Silva A., McManamy O., Ingley K., Strauss SJ. Exceptional disease response with the MDM2 inhibitor, Brigimadlin in a patient with multiply-treated MDM2 amplified metastatic intimal sarcoma of the heart. British Sarcoma Group Annual Conference, 27-28 February 2024, Leeds, United Kingdom.

20/10/2023 – 24/10/2024

### **1312MO Combining the antigen-presenting cell activator efitlagimod alpha (soluble {LAG}-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II)**

---

Carcereny E, Felip E, Majem M, Doger de Spéville B, Clay TD, Bondarenko I, Peguero J, Cobo Dols M, Forster MD, Ursol G, Kalinka E, Garcia Ledo GM, Vila Martinez L, Iams W, Krebs MG, Kefas J, Efthymiadis K, Perera S, Mueller C, Triebel F. 1312MO Combining the antigen-presenting cell activator efitlagimod alpha (soluble {LAG}-3) and pembrolizumab: Overall survival data from the first line non-small cell lung carcinoma (NSCLC) cohort of TACTI-002 (phase II). ESMO 2023, 20-24 October 2023, Madrid, Spain.

10/05/2023 – 12/05/2023

### **Use of artificial intelligence for the automatic assessment of left ventricular ejection fraction by oncology staff in chemotherapy patients**

---

Papadopoulou SL, Dionysopoulos D, Montesidou V, Loga K, Michalopoulou S, Koukoutzeli C, Efthymiadis K, Kantartzi V, Styliadis I, Nihoyannopoulos P, Sachpekidis V. EACVI 2023, 10-12 May 2023, Barcelona, Spain.

21/10/2009 – 24/10/2009

## **Decline in Sex ratio at birth and fetal deaths in Greece: The toxic effect hypothesis**

---

Miliaras D., Efthymiadis K., Meditskou S. Decline in Sex ratio at birth and fetal deaths in Greece: The toxic effect hypothesis. Medichem International Workshop and Mini Symposium: Risk Assessment and Human Exposure to Hazardous materials, 21-24 October 2009, Thessaloniki, Greece.

21/09/2005 – 24/09/2005

## **Effect of fruit epicuticular waxes on the photodegradation of chlorpyrifos-methyl**

---

Riccio R., Nicelli M., Efthymiadis K., Del Re AA., Capri E. Effect of fruit epicuticular waxes on the photodegradation of chlorpyrifos-methyl. 4th MGPR International Symposium and Annual Meeting, 21-24 September 2005, Kusadasi-Aydin, Turkey.

## ● **ABSTRACTS AND POSTERS IN NATIONAL CONFERENCES**

---

05/04/2023 – 08/04/2023

### **Sarcomas: Clinical characteristics and therapeutic options- Real world data from a Quaternary Care hospital in Thessaloniki**

---

Mentesidou V., Lallas K., Valoukas D., Dionysopoulos D., Lazaridis G., Efthymiadis K., Timotheadou E., Sogka E. Sarcomas: Clinical characteristics and therapeutic options- Real world data from a Quaternary Care hospital in Thessaloniki. 29th Hellenic Congress of Medical Oncology "Science, Technology, Human", 5-8 April 2023, Athens, Greece.

04/05/2022 – 07/05/2022

### **The supremacy of multiple gene panel for the molecular analysis of patients with lung cancer**

---

Tsantikidi K., Metaxa-Mariatou V., Florou-Chatzigiannidou Ch., Meidani A., Maravelaki S., Kapetsis G., Tsaousis G., Bourkoulas E., Fotiou D., Michala A., Potska K., Letsa I., Zervas E., Samitas K., Efthymiadis K., Floros Th., Mountzios I., Kosmidis P., Karanikiotis Ch., Tsiouda Th., Botsolis K., Kamplatsas E., Adamidis A., Papadopoulou E., Nasioulas G. The supremacy of multiple gene panel for the molecular analysis of patients with lung cancer. 6th Greek Conference of Medical Oncology "Oncology 2022, Citius, Altius, Fortius", 4-7 May 2022, Thessaloniki, Greece.

04/05/2022 – 07/05/2022

### **Testing of newly diagnosed advanced high grade ovarian cancer (OC) patients with the Myriad Genetics MyChoice CDx Plus next generation sequencing-based in vitro diagnostic test emphasizes the need for public insurance coverage of genetic testing: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO)**

---

Liontos M., Timotheadou E., Saloustros Em., Koumariou A., Athanasiadis I., Karageorgopoulou S., Papakotoulas P., Syrios I., Kesisis G., Papadimitriou Ch., Bizioti E., Skondra M., Giassas S., Kamplatsas E., Peroukidis S., Christodoulou Ch., Kantzioura A., Nikolaou M., Papaxoinis G., Soupos N., Fotarelli A., Emmanouilidis Ch., Kotsakis A., Mavroudis D., Bokas A., Stamatopoulou S., Tolis Ch., Mauri D., Anagnostopoulos A., Georgoulas V., Korantzis I., Koutras A., Koutsoukos K., Papadopoulos G., Papanikolaou S., Poupitsis A., Romanidou O., Toutoutoglou N., Tsiara A., Floros Th., Agorastos A., Adamidis A., Andreadis Ch., Andreadou A., Gouveris P., Demiri S., Dimoudis S., Kalykaki A., Kanakoulou D., Kapodistrias N., Makatsoris Th., Mountzios I., Botsolis K., Nasi D., Douvelis E., Xanthakis I., Economopoulou P., Papazisis K., Perdikouri E.I., Pispirigkou M., Plearchopoulou K., Razis E., Rallis G., Rapti K., Stamati D., Stefanou D., Tzanninis D., Tryfonopoulos D., Fassas A., Fountzila E., Charalampakis N., Chatsidis G., Christopoulou A., Aravantinos G., Ardavanis A., Efthymiadis K., Zagouri F., Zakopoulou R., Zarkavelis G., Zafeiriou Z., Ziogas D., Zlatintsi S., Thomopoulou K., Kalofonos Ch., Kaltsas S., Karanikiotis Ch., Katopodi O., Kosmas Ch., Kosmidis P., Kourousis Ch., Kostadima L., Lampropoulos S., Laschos K., Levva S., Lianos E., Makrantonakis P., Maragkos Ch., Mitsimponas N., Michalaki V., Barbounis V., Bafaloukos D., Boutis A., Neanidis K., Nikiforidis L., Nikolakopoulos A., Doufexis D., Economopoulos G., Orfanos G., Panou M., Papanastopoulos P., Papafili A., Paraskeva M., Pectasides E., Petrakis D., Rigakos G., Rigas G., Spathas N., Sfika A., Tegos Th., Tzovaras A., Tripodaki E.S., Tsoukalas N., Papageorgiou F., Boukovinas I., Saridaki Z. Testing of newly diagnosed advanced high grade ovarian cancer (OC) patients with the Myriad Genetics MyChoice CDx Plus next generation sequencing-based in vitro diagnostic test emphasizes the need for public insurance coverage of genetic testing: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO). 6th Greek Conference of Medical Oncology "Oncology 2022, Citius, Altius, Fortius", 4th-7th May 2022, Thessaloniki, Greece.

04/05/2022 – 07/05/2022

### **Molecular epidemiology and real world data in patients with advanced lung cancer and epidermal growth factor receptor mutations in exon 20: First registry from the European database EXOTIC**

---

Mountzios I., Planchard D., Metro G., Pretaj A., Tsiouda D., Shalata W., Riudavets M., Christopoulos P., Girard N., Albarran V., Garcia Campelo R., Samitas K., Zervas E., Banna G., Boukovinas I., Agbarya A., Koumarianou A., Perdikouri E.I., Papatsimpas G., Linardou E., Mauri D., Mavroudis D., Athanasiadis I., Kalofonos Ch., Xenidis N., Korantzis I., Ardavanis A., Rallis G., Efthymiadis K., Economopoulou P., Economopoulos G., Tsoukalas N., Psyrris A., Kosmidis P., Reck M., Lo Russo G. Molecular epidemiology and real world data in patients with advanced lung cancer and epidermal growth factor receptor mutations in exon 20: First registry from the European database EXOTIC. First quality prize for oral presentation in the 6th Greek Conference of Medical Oncology "Oncology 2022, Citius, Altius, Fortius", 4-7 May 2022, Thessaloniki, Greece.

18/04/2019 – 20/04/2019

### **Geriatric assessment of Cancer Patients using G8 test: a prospective study of the Aristotle University of Thessaloniki Medical Oncology Department. 25th Hellenic Congress of Medical Oncology**

---

Lewva S., Polychronidou G., Fountzila E., Koliou P., Efthymiadis K., Adamidis A., Tzelepi V., Lazaridis G., Dionysopoulos D., Timotheadou E., Papandreou C. Geriatric assessment of Cancer Patients using G8 test: a prospective study of the Aristotle University of Thessaloniki Medical Oncology Department. 25th Hellenic Congress of Medical Oncology, 18-20 April 2019, Athens, Greece.

10/10/2019 – 13/10/2019

### **The role of bowel microbiome in cancer immunotherapy**

---

Kamperis E., Efthymiadis K., Gazani G., Kodona Ch., Gkortsou D., Giannouzakos V. The role of bowel microbiome in cancer immunotherapy. 39th Panhellenic Congress of Gastroenterology, 10-13 October 2019, Alexandroupoli, Greece.

10/10/2019 – 13/10/2019

### **The role of stereotactic radiotherapy in pancreatic cancer**

---

Kamperis E., Efthymiadis K., Gazani G., Kodona Ch., Gkortsou D., Giannouzakos V. The role of stereotactic radiotherapy in pancreatic cancer. 39th Panhellenic Congress of Gastroenterology, 10-13 October 2019, Alexandroupoli, Greece.

10/10/2019 – 13/10/2019

### **Stereotactic radiotherapy in colon cancer oligometastatic disease**

---

Kamperis E., Efthymiadis K., Gazani G., Kodona Ch., Gkortsou D., Giannouzakos V. Stereotactic radiotherapy in colon cancer oligometastatic disease. 39th Panhellenic Congress of Gastroenterology, 10-13 October 2019, Alexandroupoli, Greece.

10/10/2019 – 13/10/2019

### **Artificial intelligence applications in Gastroenterology**

---

Kamperis E., Efthymiadis K., Gazani G., Kodona Ch., Gkortsou D., Giannouzakos V. Artificial intelligence applications in Gastroenterology. 39th Panhellenic Congress of Gastroenterology, 10-13 October 2019, Alexandroupoli, Greece.

21/04/2016 – 23/04/2016

### **Real-time data registry and survival analysis in patients with non-small cell lung cancer (NSCLC) who received chemotherapy in the AUTH Medical Oncology Department**

---

Lewva S., Polychronidou G., Koliou P., Efthymiadis K., Fountzila E., Adamidis A., Zarali O., Zairi E., Timotheadou E., Dionysopoulos D. Real-time data registry and survival analysis in patients with non-small cell lung cancer (NSCLC) who received chemotherapy in the AUTH Medical Oncology Department. 3rd Hellenic Congress of Oncology; 22th Panhellenic Conference of Medical Oncology, 15th Panhellenic Conference of Clinical Oncology, 21-23 April 2016, Ioannina, Greece.

21/04/2016 – 23/04/2016

### **The use of catheters port-a-cath in patients with solid tumors and its complications during the years 2011-2015: Practice from the University Medical Oncology Department of the Aristotle University of Thessaloniki, Papageorgiou General Hospital**

---

Koliou P., Fountzila E., Lewva S., Efthymiadis K., Tsiviki A., Kiranou M., Patsiavoura D., Maleza I., Roumkou S., Polychronidou G., Adamidis A., Zarali O., Zairi E., Perdikouri E.-I., Rallis Gr., Dionysopoulos D., Karavasilis V., Timotheadou E. The use of catheters port-a-cath in patients with solid tumors and its complications during the years 2011-2015: Practice from the University Medical Oncology Department of the Aristotle University of Thessaloniki, Papageorgiou General Hospital. 3rd Hellenic Congress of Oncology; 22th Panhellenic Conference of Medical Oncology, 15th Panhellenic Conference of Clinical Oncology, 21-23 April 2016, Ioannina, Greece.

21/04/2016 – 23/04/2016

### **Incidence of thromboembolic disease in cancer patients of the University Medical Oncology Department of Aristotle University of Thessaloniki in the year 2015.**

---

Koliou P., Fountzila E., Levva S., Efthymiadis K., Polychronidou G., Adamidis A., Zarali O., Perdikouri E.-I., Rallis Gr., Dionysopoulos D., Karavasilis V., Timotheadou E. Incidence of thromboembolic disease in cancer patients of the University Medical Oncology Department of Aristotle University of Thessaloniki in the year 2015. 3rd Hellenic Congress of Oncology; 22th Panhellenic Conference of Medical Oncology, 15th Panhellenic Conference of Clinical Oncology, 21-23 April 2016, Ioannina, Greece.

20/11/2014 – 22/11/2014

### **ICU readmission reasons and patient outcome following major lung parenchyma resections**

---

Rallis T., Paliouras D., Gogakos A., Lazopoulos A., Efthymiadis K., Fotarelli A., Asteriou C., Barbetakis N. ICU readmission reasons and patient outcome following major lung parenchyma resections. 10th Panhellenic Congress of the Hellenic Cardio-Thoracic Surgeons Society & 1st World Meeting of the Hellenic Cardiothoracic Diaspora, 20-22 November 2014, Athens, Greece.

25/04/2013 – 27/04/2013

### **Clinical benefit in patients with advanced breast cancer treated with trastuzumab and lapatinib**

---

Chatzileontiadou S., Boutis A., Diamantopoulos N., Pouptsis A., Efthymiadis K., Fountoukidis G., Zlatintzi S., Fotiou C. Clinical benefit in patients with advanced breast cancer treated with trastuzumab and lapatinib. 19th Panhellenic Conference of Medical Oncology, 13rd Panhellenic Congress of Clinical Oncology, 25-27 April 2013, Athens, Greece.

25/04/2013 – 27/04/2013

### **Cardiotoxicity of combined chemotherapy with 5-fU and trastuzumab in a patient with metastatic gastroesophageal junction cancer**

---

Didagelos M., Efthymiadis K., Pouptsis A., Diamantopoulos N., Fotiou C., Lafaras C. Cardiotoxicity of combined chemotherapy with 5-fU and trastuzumab in a patient with metastatic gastroesophageal junction cancer. 19th Panhellenic Conference of Medical Oncology, 13rd Panhellenic Congress of Clinical Oncology, 25-27 April 2013, Athens, Greece.

07/07/2010 – 07/07/2010

### **Social groups which most often visit primary care services**

---

Efthymiadis K. Social groups which most often visit primary care services. 1st Annual Meeting of Primary Care and General Practice Trainers, 7 July 2010, Thessaloniki, Greece.

## ● **ORAL PRESENTATIONS IN NATIONAL CONFERENCES**

---

09/04/2025 – 12/04/2025

### **The role of artificial intelligence in the emergence of new biomarkers**

---

Efthymiadis K. The role of artificial intelligence in the emergence of new biomarkers. 31st Hellenic Congress of Medical Oncology (HeCMO) "We made time for the things that matter", 9-12 April 2025, Athens, Greece.

27/03/2025 – 29/03/2025

### **Therapeutic advances in small cell lung cancer**

---

Efthymiadis K. Therapeutic advances in small cell lung cancer. 4th Panhellenic Congress of Cancer Therapeutics, 27-29 March 2025, Thessaloniki. Greece.

22/02/2025 – 22/02/2025

### **Understanding Cancer Disease, Prevention and Treatment**

---

Efthymiadis K. Understanding Cancer Disease, Prevention and Treatment. Particle Therapy Masterclass, CERN- Conseil Européen pour la Recherche Nucléaire, GSI - Helmholtzzentrum für Schwerionenforschung GmbH, 22 February 2025, online.

22/11/2024 – 23/11/2024

### **Immunotherapy rechallenge, retreatment and resumption**

---

Efthymiadis K. Immunotherapy rechallenge, retreatment and resumption. Interdisciplinary collaboration at the Anti-Cancer Hospital. 22-23 November 2024, Thessaloniki, Greece.

07/11/2024 – 08/11/2024

### **Neo-adjuvant chemotherapy in borderline and locally advanced PDAC**

---

Efthymiadis K. Neo-adjuvant chemotherapy in borderline and locally advanced PDAC. Innovation in Surgery and Oncology - A European Forum in Greece, European Interbalkan Medical Center, 7-8 November 2024, Thessaloniki, Greece.

01/11/2024 – 02/11/2024

### **Neoadjuvant vs adjuvant treatment in resectable melanoma; clinical trials and reality (Clinical studies and Real- world studies)**

---

Efthymiadis K. Neoadjuvant vs adjuvant treatment in resectable melanoma; clinical trials and reality (Clinical studies and Real- world studies). 16th Postgraduate Seminar of Medical Oncology, 1-2 November 2024, Thessaloniki, Greece.

31/10/2024 – 31/10/2024

### **Best of ESMO 2024- Session 3: Artificial Intelligence in Oncology**

---

Efthymiadis K. Best of ESMO 2024- Session 3: Artificial Intelligence in Oncology. HeSMO Webinar Best of ESMO 2024, 31st October 2024, online.

20/09/2024 – 22/09/2024

### **PD-1 refractory melanoma; How do we reach latest line of treatment?**

---

Efthymiadis K. PD-1 refractory melanoma; How do we reach latest line of treatment? The Optimal Sequencing in the Era of Multiple Therapeutic Options, 20-22 September 2024, Thessaloniki, Greece.

28/03/2024 – 30/03/2024

### **1st line immunotherapy with checkpoint inhibitors in non-small cell lung cancer**

---

Efthymiadis K. 1st line immunotherapy with checkpoint inhibitors in non-small cell lung cancer. 3rd Panhellenic Congress of Cancer Therapeutics, 28-30 March 2024, Thessaloniki. Greece.

23/03/2024 – 23/03/2024

### **Understanding Cancer Disease, Prevention and Treatment**

---

Efthymiadis K. Understanding Cancer Disease, Prevention and Treatment. Particle Therapy Masterclass, Conseil Européen pour la Recherche Nucléaire, GSI - Helmholtzzentrum für Schwerionenforschung GmbH, Aristotle University of Thessaloniki, National Center for Scientific Research “Demokritos”, “Papageorgiou” Thessaloniki General Hospital, 23 March 2024, online.

27/02/2024 – 28/02/2024

### **Exceptional disease response with the MDM2 inhibitor, Brigimadlin in a patient with multiply-treated MDM2 amplified metastatic intimal sarcoma of the heart**

---

Efthymiadis K. Exceptional disease response with the MDM2 inhibitor, Brigimadlin in a patient with multiply-treated MDM2 amplified metastatic intimal sarcoma of the heart. British Sarcoma Group Annual Conference, 27-28 February 2024, Leeds, United Kingdom.

27/01/2024 – 27/01/2024

### **The role of immunotherapy in metastatic colon carcinoma**

---

Efthymiadis K. The role of immunotherapy in metastatic colon carcinoma. Symposium with subject: “The application of molecular targeted therapies and immunotherapy in solid tumors, 27 January 2024, Thessaloniki, Greece.

03/11/2023 – 04/11/2023

### **The benefit of immunotherapy rechallenge in recurrent melanoma: challenges and disputes**

---

Efthymiadis K. The benefit of immunotherapy rechallenge in recurrent melanoma: challenges and disputes. 15th Postgraduate Seminar of Medical Oncology, 3-4 November 2023, Thessaloniki, Greece.

15/09/2023 – 16/09/2023

### **Triple negative breast cancer- therapeutic options**

---

Efthymiadis K. Triple negative breast cancer- therapeutic options. The Optimal Sequencing in the Era of Multiple Therapeutic Options, 15-16 September 2023, Thessaloniki, Greece.

01/09/2023 – 02/09/2023

### **Early testicular cancer**

---

Efthymiadis K. Early testicular cancer. Current topics on respiratory and genitourinary cancer. 1-2 September 2023, Thessaloniki, Greece.

26/05/2023 – 27/05/2023

### **Immunotherapy in early NSCLC. Pre- or post- operatively?**

---

Efthymiadis K. Immunotherapy in early NSCLC. Pre- or post- operatively? Cancer 2023, 26-27 May 2023, Thessaloniki, Greece.

30/03/2023 – 01/04/2023

### **Treatment of advanced NSCLC with no driver mutation**

---

Efthymiadis K. Treatment of advanced NSCLC with no driver mutation. 2nd Panhellenic Congress of Cancer Therapeutics, 30 March- 1 April 2023, Thessaloniki. Greece.

04/03/2023 – 04/03/2023

### **Understanding Cancer Disease, Prevention and Treatment**

---

Efthymiadis K. Understanding Cancer Disease, Prevention and Treatment. Particle Therapy Masterclass, Conseil Européen pour la Recherche Nucléaire, GSI - Helmholtzzentrum für Schwerionenforschung GmbH, Aristotle University of Thessaloniki, National Center for Scientific Research "Demokritos", "Papageorgiou" Thessaloniki General Hospital, 4 March 2023, online.

21/01/2023 – 21/01/2023

### **Therapeutic approaches in metastatic pancreatic cancer**

---

Efthymiadis K. Therapeutic approaches in metastatic pancreatic cancer. Symposium with subject "The application of molecular targeted therapies and immunotherapy in solid tumors, 21 January 2023, Thessaloniki, Greece.

04/11/2022 – 05/11/2022

### **The specificities of the results of treatment with immunotherapy in bladder cancer**

---

Efthymiadis K. The specificities of the results of treatment with immunotherapy in bladder cancer. 14th Postgraduate Seminar of Medical Oncology, 4-5 November 2022, Thessaloniki, Greece.

14/10/2022 – 16/10/2022

### **Latest therapeutic developments in Lung Cancer- Targeting KRAS mutation**

---

Efthymiadis K. Latest therapeutic developments in Lung Cancer- Targeting KRAS mutation. Newer data on the Prevention and Treatment of Lung Cancer IV, 14-16 October 2022, Thessaloniki, Greece.

30/09/2022 – 02/10/2022

### **Neoadjuvant/ adjuvant treatment of lung cancer**

---

Efthymiadis K. Neoadjuvant/ adjuvant treatment of lung cancer. Innovation in Oncology IV, 30 September-2 October 2022, Thessaloniki, Greece.

29/09/2022 – 30/09/2022

### **Oncological approach to pancreatic cancer**

---

Efthymiadis K. Oncological approach to pancreatic cancer. British-Greek Surgical Forum, The UK Surgical Travellers visit to Thessaloniki 2022, 29-30 September 2022, Thessaloniki, Greece.

16/09/2022 – 17/09/2022

### **Bispecific and conjugated monoclonal antibodies in the treatment of patients with advanced NSCLC with driver mutations**

---

Efthymiadis K. Bispecific and conjugated monoclonal antibodies in the treatment of patients with advanced NSCLC with driver mutations. The Optimal Sequencing in the Era of Multiple Therapeutic Options, 16-17 September 2022, Thessaloniki, Greece.



16/06/2022 – 18/06/2022

## **Recent developments in Thoracic Oncology- ASCO Congress. Non-small cell lung cancer**

---

Efthymiadis K. Recent developments in Thoracic Oncology- ASCO Congress. Non-small cell lung cancer. 1st Congress on Lung Cancer- Form research to clinical practice, 16-18 June 2022, Athens, Greece.

27/05/2022 – 28/05/2022

## **SCLC, Molecular Subtypes and their Prognostic Value, Therapeutic Options**

---

Efthymiadis K. SCLC, Molecular Subtypes and their Prognostic Value, Therapeutic Options. Cancer 2022, 27-28 May 2022, Thessaloniki, Greece.

09/04/2022 – 09/04/2022

## **Understanding Cancer Disease, Prevention and Treatment**

---

Efthymiadis K. Understanding Cancer Disease, Prevention and Treatment. Particle Therapy Masterclass, Conseil Européen pour la Recherche Nucléaire, GSI - Helmholtzzentrum für Schwerionenforschung GmbH, Aristotle University of Thessaloniki, National Center for Scientific Research "Demokritos", "Papageorgiou" Thessaloniki General Hospital, 9 April 2022, online.

31/03/2022 – 02/04/2022

## **Extending overall survival in mTNBC: the role of immunotherapy**

---

Efthymiadis K. Extending overall survival in mTNBC: the role of immunotherapy. Panhellenic Congress of Cancer Therapeutics, 31 March- 2 April 2022, Thessaloniki. Greece.

18/11/2021 – 21/11/2021

## **Improving treatment of recurrent endometrial cancer**

---

Efthymiadis K. Improving treatment of recurrent endometrial cancer. Congress of Clinical and Translational Oncology, 18-21 November 2021, Heraklion, Greece.

12/11/2021 – 14/11/2021

## **Molecular subtypes of SCLC and their role on treatment options**

---

Efthymiadis K. Molecular subtypes of SCLC and their role on treatment options. 3rd Northern Greece Oncology Clinical Lessons, 12-14 November 2021, Trikala, Greece.

06/11/2021 – 06/11/2021

## **Neoadjuvant Endocrine Therapy, Data Update. Section: Special Topics on Neoadjuvant Treatment**

---

Efthymiadis K. Neoadjuvant Endocrine Therapy, Data Update. Section: Special Topics on Neoadjuvant Treatment. Greek Breast Surgery Society, Webinars Online Seminars, Fall- Winter 2021. 3rd Webinar "Neoadjuvant therapy in breast cancer", 6 November 2021, online.

05/11/2021 – 06/11/2021

## **Urinary Bladder Cancer: "Neoadjuvant- adjuvant treatment"**

---

Efthymiadis K. Urinary Bladder Cancer: "Neoadjuvant- adjuvant treatment". Scientific Meeting "Current Topics on Gynecological and Urological Cancer", 5-6 November 2021, Thessaloniki, Greece.

08/10/2021 – 09/10/2021

## **CdK4/6i: Comparative real world clinical data in the 1st line treatment of ER+/HER2- mBC**

---

Efthymiadis K. CdK4/6i: Comparative real world clinical data in the 1st line treatment of ER+/HER2- mBC. Educational Seminar: Breast Cancer/ Melanoma 2021, 8-9 October 2021, Thessaloniki, Greece.

01/10/2021 – 03/10/2021

## **Targeting novel biomarkers in NSCLC: KRASG12C mutation**

---

Efthymiadis K. Targeting novel biomarkers in NSCLC: KRASG12C mutation. Newer data on the Prevention and Treatment of Lung Cancer III, 1-3 October 2021, Thessaloniki, Greece.

24/09/2021 – 26/09/2021

## **Treatment of Small Cell Lung Cancer: Is there Light in the Tunnel?**

---

Efthymiadis K. Treatment of Small Cell Lung Cancer: Is there Light in the Tunnel? 9th Panhellenic Congress of the Research Society of Urogenital Oncology, Thessaloniki, 24-26 September 2021

10/09/2021 – 11/09/2021

### **Novel drugs and their combinations for overcoming EGFR TKI resistance**

---

Efthymiadis K. Novel drugs and their combinations for overcoming EGFR TKI resistance. The Optimal Sequencing in the Era of Multiple Therapeutic Options, 10-11 September 2021, Thessaloniki, Greece.

01/07/2021 – 03/07/2021

### **Microbiome**

---

Efthymiadis K. Microbiome. HeGYO Symposium "New Journeys in Oncology" as part of the "12th Postgraduate Seminar of Clinical and Research Oncology", 1st-3rd July 2021, Athens, Greece.

25/06/2021 – 27/06/2021

### **Driver mutation KRASG12C in patients with NSCLC**

---

Efthymiadis K. Driver mutation KRASG12C in patients with NSCLC. Cancer 2021- Guidelines, 25- 27 June 2021, Thessaloniki, Greece.

18/06/2021 – 19/06/2021

### **Therapeutic developments in the management of Small Cell Lung Cancer- the Effect of Molecular Subtypes on Treatment**

---

Efthymiadis K. Therapeutic developments in the management of Small Cell Lung Cancer- the Effect of Molecular Subtypes on Treatment. Session "Lung Cancer" as part of the Web Scientific Event "Urogenital Cancer (prostate, bladder, kidney), Developments in Oncology", 18-19 June 2021, online.

27/05/2021 – 29/05/2021

### **Is there an algorithm in Castration Resistant Metastatic Prostate Cancer?**

---

Efthymiadis K. Is there an algorithm in Castration Resistant Metastatic Prostate Cancer? Panhellenic Congress with subject "Current Subjects in Oncology", 27-29 May 2021, Thessaloniki, Greece.

19/05/2021 – 19/05/2021

### **1st line treatment setting of Small Cell Lung Cancer, Case Study**

---

Efthymiadis K. 1st line treatment setting of Small Cell Lung Cancer, Case Study. Scientific Meeting for the Management of Lung Cancer: Newer data, 19 May 2021, online.

06/05/2021 – 06/05/2021

### **Long-term remission on immunotherapy: discontinuation or continuation?**

---

Efthymiadis K. Long-term remission on immunotherapy: discontinuation or continuation? Postgraduate Oncology Lessons, 2nd Lesson: Lung Cancer, 6 May 2021, online.

06/03/2021 – 06/03/2021

### **Understanding Cancer Disease, Prevention and Treatment**

---

Efthymiadis K. Understanding Cancer Disease, Prevention and Treatment. Particle Therapy Masterclass, Conseil Européen pour la Recherche Nucléaire, GSI - Helmholtzzentrum für Schwerionenforschung GmbH, Aristotle University of Thessaloniki, National Center for Scientific Research "Demokritos", "Papageorgiou" Thessaloniki General Hospital, 6 March 2021, online.

10/02/2021 – 10/02/2021

### **What is Total Mesocolic Excision. What is its place on current definitive surgical management of colon adenocarcinoma? The view of the Medical Oncologist**

---

Efthymiadis K. What is Total Mesocolic Excision. What is its place on current definitive surgical management of colon adenocarcinoma? The view of the Medical Oncologist. Postgraduate Lessons of the Northern Greece Surgical Society, 5th lesson: "Definitive Surgical Treatment of Colon Adenocarcinoma", 10 February 2021, online.

04/12/2020 – 05/12/2020

### **Immunotherapy as a weapon in the management of triple negative breast cancer**

---

Efthymiadis K. Immunotherapy as a weapon in the management of triple negative breast cancer. Educational Seminar: Breast Cancer/ Melanoma 2020, 4-5 December 2020, online.

17/11/2020 – 17/11/2020

### **Management of EGFR mutated disease and overcoming resistance**

---

Efthymiadis K. Management of EGFR mutated disease and overcoming resistance. Webinar Cycle “Current Subjects on Oncology: Lung Cancer”, 17 November 2020, online.

12/11/2020 – 14/11/2020

### **Cancer Immunotherapy: Optimizing the effectiveness of checkpoints**

---

Efthymiadis K. Cancer Immunotherapy: Optimizing the effectiveness of checkpoints. Congress on Clinical and Translational Oncology, 12-14 November 2020, online.

15/10/2020 – 17/10/2020

### **Neoadjuvant chemotherapy in breast cancer**

---

Efthymiadis K. Lecture: “Neoadjuvant chemotherapy in breast cancer”. 35th Northern Greece Medicine Congress, 15-17 October 2020, Thessaloniki, Greece.

15/10/2020 – 17/10/2020

### **Neoadjuvant chemotherapy: Choosing the best strategy- Novel Therapeutic Options: Breast Cancer**

---

Efthymiadis K. Neoadjuvant chemotherapy: Choosing the best strategy- Novel Therapeutic Options: Breast Cancer. 35th Northern Greece Medicine Congress, 15-17 October 2020, Thessaloniki, Greece.

02/07/2020 – 04/07/2020

### **Newer data on the therapeutic management of ALK+ disease in NSCLC**

---

Efthymiadis K. Newer data on the therapeutic management of ALK+ disease in NSCLC. Innovation in Oncology II, 2-4 July 2020, Thessaloniki, Greece.

11/09/2020 – 13/09/2020

### **(Chemo)Immunotherapy in Small Cell Lung Cancer- Newer Data**

---

Efthymiadis K. (Chemo)Immunotherapy in Small Cell Lung Cancer- Newer Data. Session “Lung Cancer” as part of the 8th Panhellenic Congress of the Research Society of Urogenital Oncology, 11-13 September 2020, Thessaloniki, Greece.

03/07/2020 – 04/07/2020

### **Everyday challenges in the management of patients with lung cancer- Lighting the pathway through dialogue, ASCO highlights**

---

Efthymiadis K. Everyday challenges in the management of patients with lung cancer- Lighting the pathway through dialogue, ASCO highlights. Cancer 2020- Guidelines, 3-4 July 2020, Thessaloniki, Greece.

03/07/2020 – 04/07/2020

### **HRD high breast cancer: Do eventually we modify surgical- radiotherapeutic and systemic treatment when interpreting multi genomic tests?**

---

Efthymiadis K. HRD high breast cancer: Do eventually we modify surgical- radiotherapeutic and systemic treatment when interpreting multi genomic tests? Cancer 2020- Guidelines, 3-4 July 2020, Thessaloniki, Greece.

20/02/2020 – 22/02/2020

### **Clonal evolution of metastatic disease**

---

Efthymiadis K. Clonal evolution of metastatic disease. 11th Postgraduate Seminar of Medical and Research Oncology. 20-22 February 2020, Athens, Greece.

07/02/2020 – 08/02/2020

### **Immunotherapy in Breast Cancer, victories and defeats. Concerns in gynecological malignancies, cancer of the ovaries, uterus and breast**

---

Efthymiadis K. Immunotherapy in Breast Cancer, victories and defeats. Concerns in gynecological malignancies, cancer of the ovaries, uterus and breast. 7-8 February 2020, Thessaloniki, Greece.

13/12/2019 – 14/12/2019

### **New data on the treatment of metastatic prostate cancer**

---

Efthymiadis K. New data on the treatment of metastatic prostate cancer. 17th Postgraduate Congress, Developments in Oncology, 13-14 December 2019, Rio, Greece.

14/11/2019 – 17/11/2019

### **Low grade ovarian cancer, a different approach**

---

Efthymiadis K. Low grade ovarian cancer, a different approach. Congress of Medical and Translational Oncology and Congress on Breast Cancer, 14-17 November 2019, Heraklion, Greece.

20/09/2019 – 22/09/2019

### **Breast cancer, developments in the treatment of HER2+ disease**

---

Efthymiadis K. Breast cancer, developments in the treatment of HER2+ disease. 7th Panhellenic Congress of the Research Society of Urogenital Oncology, 20-22 September 2019, Thessaloniki, Greece.

13/09/2019 – 15/09/2019

### **Treatment sequencing in hormone-resistant prostate cancer**

---

Efthymiadis K. Treatment sequencing in hormone-resistant prostate cancer. Congress with subject "Optimal sequencing in the era of multiple therapeutic options, 13-15 September 2019, Thessaloniki, Greece.

13/09/2019 – 15/09/2019

### **Treatment sequencing in hormone-resistant prostate cancer**

---

Efthymiadis K. Treatment sequencing in hormone-resistant prostate cancer. Congress with subject "Optimal sequencing in the era of multiple therapeutic options, 13-15 September 2019, Thessaloniki, Greece.

07/06/2019 – 09/06/2019

### **Novel androgen blockade agents: Early VS late use in prostate cancer treatment algorithm**

---

Efthymiadis K. Novel androgen blockade agents: Early VS late use in prostate cancer treatment algorithm. 4th Scientific Meeting "Oncology on the verge of new developments", 7-9 June 2019, Kastoria, Greece.

16/02/2019 – 16/02/2019

### **Lung Cancer Micromutations: cMET**

---

Efthymiadis K. Lung Cancer Micromutations: cMET. Scientific meeting with subject "Unlocking Lung Cancer- Adapting therapy on biology", 16 February 2019, Thessaloniki, Greece.

08/06/2018 – 10/06/2018

### **Newest data on advanced urothelial cancer**

---

Efthymiadis K. Newest data on advanced urothelial cancer. 3rd Scientific Meeting "Oncology on the verge of new developments", 8-10 June 2018, Kastoria, Greece.

11/05/2018 – 12/05/2018

### **Immunotherapy: Approved options in gastrointestinal tumors. Malignant gastrointestinal tumors, Progress and newer data**

---

Efthymiadis K. Immunotherapy: Approved options in gastrointestinal tumors. Malignant gastrointestinal tumors, Progress and newer data, 11-12 May 2018, Thessaloniki, Greece.

17/04/2018 – 17/04/2018

### **Musculoskeletal cancer management through Multidisciplinary Tumor Board, presentation of 4 cases**

---

Efthymiadis K. Musculoskeletal cancer management through Multidisciplinary Tumor Board, presentation of 4 cases. Thessaloniki Medical Association Lessons, Postgraduate Orthopedic Lessons 2018, 17 April 2018, Thessaloniki, Greece.

22/09/2017 – 24/09/2017

### **Case Report: Patient with hormone-naïve oligometastatic prostate adenocarcinoma**

---

Efthymiadis K. Case Report: Patient with hormone-naïve oligometastatic prostate adenocarcinoma. 5th Panhellenic Congress of the R.S.U.O., Modern Approach of GI and Urological Cancers, 22-24 September 2017, Thessaloniki, Greece.

09/10/2015 – 11/10/2015

### **Case Report: Patient with marrow compression, CNS infiltration and hypercalcaemia**

---

Efthymiadis K. Case Report: Patient with marrow compression, CNS infiltration and hypercalcaemia. HeGYO Meeting on Acute Oncology, 11 October 2015, during the proceedings of the 8th Medical Oncology Seminar, 9-11 October 2015, Thessaloniki, Greece.

28/03/2015 – 29/03/2015

### **Long-term survival in patients with metastatic melanoma after GI metastasectomy**

---

Efthymiadis K. Long-term survival in patients with metastatic melanoma after GI metastasectomy. 3rd Symposium on Medical Oncology, 28-29 March 2015, Rhodes, Greece.

12/12/2014 – 14/12/2014

### **Metastatic Renal Cancer, Long-Term Survival with the Cooperation of many Medical Specialties**

---

Efthymiadis K. Metastatic Renal Cancer, Long-Term Survival with the Cooperation of many Medical Specialties. Northern Greece Oncology Congress, 12-14 December 2014, Kalambaka, Greece.

05/10/2012 – 07/10/2012

### **Cardiotoxicity in a 20yo patient with stage IV gastroesophageal junction cancer, after treatment with trastuzumab and 5-fU**

---

Efthymiadis K. Cardiotoxicity in a 20yo patient with stage IV gastroesophageal junction cancer, after treatment with trastuzumab and 5-fU. 2nd Triple-subject Oncology Congress, 5-7 October 2012, Kastoria, Greece.

## ● **CLINICAL TRIAL EXPERIENCE**

---

### **Sub-Investigator in 34 Early Phase Cancer Clinical Trials (a)**

---

34. APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA).

33. Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (ARROW).

32. Afatinib for Chordoma, A phase II, single arm, multi-centre trial evaluating the efficacy of Afatinib as first-line or later-line treatment in metastatic or unresectable chordoma.

31. TAS-120-202, A phase II trial of Futibatinib in Patients With Specific FGFR Aberrations.

30. Phase 1/2 Safety, Pharmacokinetic, and Antitumor Activity Study of G1T38 in Combination with Fulvestrant in Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer after Endocrine Failure.

29. Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors (GARNET).

28. ABXCL701, A Phase 1b/2 Study of BXCL701, a Small Molecule Inhibitor of Dipeptidyl Peptidases (DPP), Administered in Combination with the Anti-Programmed Cell Death 1

(PD-1) Monoclonal Antibody Pembrolizumab (PEMBRO; Keytruda®) in Patients with mCRPC either Small Cell Neuroendocrine Prostate Cancer (SCNC; NEPC) or Adenocarcinoma Phenotype.

27. Protocol IP-IIO-622, Intratumoral injection of IP-001 following thermal ablation in patients with advanced solid tumors. A multicenter Phase 1b/2a trial in colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma patients.

26. An Open-Label, Phase 1b Study of SL-172154 (SIRPα-Fc-CD40L) Administered with Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects with Platinum-Resistant Ovarian Cancers.

25. A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of Ceralasertib in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies.

24. A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types.

23. A Modular, Open-label, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of EP0031 in Patients with Advanced RET-altered Malignancies.

22. GO42144, A Phase Ia/Ib dose- escalation and dose- expansion study evaluating the safety, pharmacokinetics, and activity of GDC-6036 as a single agent and in combination with other anti-cancer therapies in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

21. A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A\*02:01-Positive Participants with Advanced PRAME-Positive Cancers.

20. KY1044-CT01, A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination with Anti-PD-L 1 (Atezolizumab) in Adult Patients with Selected Advanced Malignancies.
  19. ModiFY, A phase 1/2, multicentre, open-label study of MODI-1 in patients with breast, head and neck, ovarian, or renal cancer.
  18. MULTI-31, An open-label, Phase II trial evaluating the safety and efficacy of BI 836880 in combination with BI 754091 in PD-(L)1 naïve and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy.
- (cont'd)

### **Sub-Investigator in 34 Early Phase Cancer Clinical Trials (b)**

---

17. PARPA-293-001, A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients with Selected Advanced/ Metastatic Solid Tumors.
16. R4018-ONC-1721, A Phase 1/2 Study of REGN4018 (A MUC16xCD3 Bispecific Antibody) Administered Alone or in Combination with Cemiplimab in Patients with Recurrent Ovarian Cancer.
15. TACTI-002 (Two ACTIVE Immunotherapeutics): A multicenter, open label, Phase II study in patients with previously untreated unresectable or metastatic non-small cell lung cancer (NSCLC), or recurrent PD-X refractory NSCLC or with recurrent or metastatic squamous head and neck cancer (HNSCC) receiving the soluble LAG-3 fusion protein eftilagimod alpha (IMP321) in combination with pembrolizumab (PD-1 antagonist).
14. TACTICAL, Targeted stromal cells expressing TRAIL as a therapy for lung cancer.
13. TAPISTRY (BO41932), Tumor-agnostic precision Immunooncology and somatic targeting rational for you (TAPISTRY), phase II platform trial.
12. TARGET National, Tumour Characterisation to Guide Experimental Targeted Therapy.
11. PATRIOT, A Phase I Study to assess the Tolerability, Safety and Biological Effects of a Specific Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor (AZD6738) as a Single Agent and in Combination with Palliative Radiation Therapy in Patients with Solid Tumours.
10. GS-US-586-6144, A Phase 2 Study of Magrolimab Combination Therapy in Patients With Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer.
9. NuTide 302, A Phase Ib/II open label study to assess the safety and pharmacokinetics of NUC-3373, a nucleotide analogue, given in combination with standard agents used in colorectal cancer treatment.
8. RLY-4008-101, A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors
7. Porcupine2 study, A Modular, Phase II, Open-Label, Multicentre Study to Assess the Preliminary Efficacy and Safety of RXC004, in Patients with Advanced Solid Tumours that have Progressed following Therapy with Current Standard of Care.
6. FURMO-002, A phase 1b dose escalation and dose expansion study evaluating the safety, pharmacokinetics, and antitumor activity of Furmonertinib in patients with advanced or metastatic non-small cell lung cancer with activating EGFR or HER2 mutations.
5. Immun sarc2, a Phase I-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas.
4. 80038114PCR1001, A Phase 1 Study of JNJ-80038114, a T-Cell Redirecting Agent Targeting Prostate Specific Membrane Antigen (PSMA), for Advanced Stage Prostate Cancer.
3. ARV-110-mCRPC-103, A Phase 1b Open-Label, Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-110 in Combination with Abiraterone in Patients with Metastatic Prostate Cancer.
2. CBT307-1, A Phase 1 Open-Label, Dose Escalation and Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of CB307, a Trispecific Humabody® T-cell Enhancer, in Patients with PSMA+ Advanced and/or Metastatic Solid Tumours (POTENTIA).
1. PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy), A First-in-human, dose titration and expansion trial to evaluate safety, immunogenicity and preliminary efficacy of W\_pro1 (BNT112) monotherapy and in combination with cemiplimab in patients with prostate cancer.

### **Sub-Investigator in 22 Late Phase Cancer Clinical Trials (a)**

---

22. Pharma Mar: Randomised, controlled, open-label, phase IIb/III study of Lurbinectedin in combination with Doxorubicin vs. Doxorubicin alone as a first-line treatment in patients with metastatic leiomyosarcoma.
21. INTER-EWING-1: International Clinical Research Programme to Improve Outcomes in Newly Diagnosed Ewing Sarcoma.
20. PEAK (CGT9486-21-301), A phase 3 randomized, open-label, multicenter clinical study of CGT9486+Sunitinib VS Sunitinib in subjects with locally advanced, unresectable, or metastatic gastrointestinal, stromal tumors.
19. Brightline-1, A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma
18. chonDRAGON, A Randomized, Blinded, Placebo-controlled, Phase 2 Study of INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma.
17. ICONIC, Improving outcomes through Collaboration in Osteosarcoma.
16. rEEcur, An International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma.

15. SPEARHEAD-01, A phase 2 single arm open-label clinical trial of ADP-A2M4 SPEARTM T cells in subjects with Advanced Synovial Sarcoma or Myxoid/ Round Cell Liposarcoma (MRCLS).
  14. PIVOT-12, Phase 3, Randomized, Open-label Study of Adjuvant Immunotherapy with Bempegaldesleukin Combined with Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Participants at High Risk for Recurrence.
  13. IidERA, A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer.
  12. SunRISe-2, A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder.
- (cont'd)

## Sub-Investigator in 22 Late Phase Cancer Clinical Trials (b)

---

11. SunRISe-1, A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy.
10. BMS-CA045-009, A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant Nivolumab Plus NKTR-214, Versus Nivolumab Alone Versus Standard of Care in Participants With Muscle-Invasive Bladder Cancer (MIBC) Who Are Cisplatin Ineligible.
9. LUCENCE, A Study of Nivolumab in Participants With Locally Advanced or Metastatic (Stage IIIB-IV) Non-Small Cell Lung Cancer (NSCLC) With Squamous and Non-Squamous Histology After Prior Chemotherapy Treated in Real World Settings in Greece and Cyprus.
8. GLOW, A Phase 3 Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
7. THOR, A Phase 3 Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Subjects With Advanced Urothelial Cancer and Selected FGFR Gene Aberrations.
6. SAMSON II, a randomized, double-blind, parallel group, equivalence, multicenter phase 3 trial to compare the efficacy, safety, pharmacokinetics and immunogenicity of HD204 to Avastin in patients with metastatic or recurrent non-squamous non-small cell lung cancer.
5. DESTINY Breast DS8201-A-U303, a multicenter, randomized, open-label, active-controlled trial of DS-8201a, an anti-HER2-antibody drug conjugate (ADC), versus treatment of physician's choice for HER2-low, unresectable and/or metastatic breast cancer subjects.
4. CARD, Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent.
3. Impassion131, A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC).
2. IPATential150, Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer.
1. monarchE, Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer.

## CHAIRMAN/ COMMENTATOR IN NATIONAL CONFERENCES

---

### Participation in National Conferences as Chairman/ Commentator (a)

---

18. Satellite lecture: "Filling the gap with dual checkpoint inhibition in patients with metastatic NSCLC and low PD-L1 expression", speaker: I. Korantzis, chair: A. Kotsakis, K. Efthymiadis. 4th Panhellenic Congress of Cancer Therapeutics, 27-29 March 2025, Thessaloniki. Greece.
17. Round table: "Lung cancer". Chair: S. Aggelaki, K. Efthymiadis, G. Lazaridis. Lecture: "The importance of screening in smokers", speaker: S. Lampaki. Lecture: "Novel data for EGFR mutations in non-small cell lung cancer", speaker: Th. Tsatsopoulos. Lecture: "The emerging role of ADCs in non-small cell lung cancer", speaker: A. Bokas. Lecture: "Therapeutic advances in small cell lung cancer", speaker: K. Efthymiadis. 4th Panhellenic Congress of Cancer Therapeutics, 27-29 March 2025, Thessaloniki. Greece.
16. Lecture: "PEComa: therapeutic options and considerations", speaker: V. Mentessidou, chair: K. Efthymiadis, S. Ntalianis, 3rd Panhellenic Congress of Cancer Therapeutics, 28-30 March 2024, Thessaloniki. Greece.
15. Lecture: "Soft tissue sarcomas: therapeutic developments", speaker: A. Kyriazoglou, chair: K. Efthymiadis, D. Valoukas, 3rd Panhellenic Congress of Cancer Therapeutics, 28-30 March 2024, Thessaloniki. Greece.
14. Satellite lecture: "Long-term survival data in metastatic NSCLC patients", speaker: E. Karamitrousis, chair: K. Efthymiadis, O. Romanidou, 3rd Panhellenic Congress of Cancer Therapeutics, 28-30 March 2024, Thessaloniki. Greece.
13. Round table: "Lung cancer and novel therapeutic approaches". Chair: D. Kasarakis, EP. Chamalidou, K. Domvri. Lecture: "Newest data on the therapeutic management of patients with NSCLC with activating insertion mutations in EGFR exon 20", speaker: A. Charpidou. Lecture: "KRAS targeting in NSCLC: present and future", speaker: A. Andreadou. Lecture: Management of rare mutations in NSCLC: BRAF- MET- HER- ROS", speaker: K. Botsolis. Commentators: An. Boutis, P. Dimopoulos, Z. Zafiriou, K. Efthymiadis, G. Lazaridis. Newer data on the Prevention and Treatment of Lung Cancer V, 15-17 September 2023, Thessaloniki, Greece.



12. Satellite lecture of the 2nd Panhellenic Congress of Cancer Therapeutics: "Evaluation of novel drug administration routes and their contribution to the National Health System". Chair: Kesisis G., Efthymiadis K. Speaker: Vozikis A. 2nd Panhellenic Congress of Cancer Therapeutics, 30 March- 1 April 2023, Thessaloniki. Greece.

11. Satellite lecture of the 2nd Panhellenic Congress of Cancer Therapeutics: "Novel therapeutic horizons through dual immune blockade in 1st line treatment of NSCLC". Chair: Kotsakis A, Efthymiadis K. Speaker: Emmanouilidis Ch. 2nd Panhellenic Congress of Cancer Therapeutics, 30 March- 1 April 2023, Thessaloniki. Greece.

10. HeGYO round table. Challenges of oncology care in special populations. Chair: Loga K., Kantzioura A., Tsiara A. Presentations: "Geriatric Oncology", speaker: Gazouli I., "AYA Oncology", speaker: Veros Ch., "Ethnic minorities and immigrants.", speaker: Pantazopoulos A., "LGBTQ", speaker: Kokkalis A. Commentary: Efthymiadis K., Pouptsis A. 6th Hellenic Conference of Oncology "Oncology 2022, Citius, Altius, Fortius", 4-7 May 2022, Thessaloniki, Greece.

(cont'd)

### **Participation in National Conferences as Chairman/ Commentator (b)**

---

9. HeGYO round table. Chair: Nikolaou M., Kantzioura A. Presentations: "HER2 positive gastric cancer.", speaker: Karatrasoglou E., commentator: Kaparelou M., "Gynecological Cancer with BRCA mutation.", speaker: Bleka E., commentator: Efthymiadis K., "Lung cancer with HER2 mutation.", speaker: Karadaglis P., commentator: Loga K., "Colon cancer with BRAF mutation.", speaker: Koulouris A., commentator: Karamitrousis E. 13th Postgraduate Seminar of Medical Oncology, 5-6 November 2021, Thessaloniki, Greece.

8. HeGYO round table, Cancer and fertility preservation. Chair: Efthymiadis K., Zagouri F., Kapodistrias N. Presentations: "Consulting on fertility preservation for cancer patients. To whom should it be offered?", speaker: Molyva D., "Fertility preservation methods", speaker Thomakos N., "Genetic counselling in patients with hereditary cancer syndromes", speaker: Mala A. Commentators: Biziota E., Skafida E., Tripodaki E.S., Tsavaris O. 27th Hellenic Conference of Medical Oncology (27th HeCMO)- "Rewriting Oncology, the New Prototype", 13-15 May 2021, Athens, Greece.

7. Satellite lecture of the Panhellenic Congress of Cancer Therapeutics. Chair: Papandreou Ch., Efthymiadis K. Presentation: "Current place of androgenic blockers in the therapeutic approach of advanced prostate cancer.", speaker: Perdikouri E.I., Panhellenic Congress of Cancer Therapeutics, 31 March- 2 April 2021, Thessaloniki, Greece.

6. Regional Seminar of Thessaloniki Medical Society: Round table of Oncology. Chairmen: Timotheadou E., Efthymiadis K. Presentations: "Acute Oncology", speaker: Zairi E., "Paraneoplastic syndromes", speaker: Koukoutzeli C., "Toxicity of Antineoplastic Agents, Diagnosis and treatment in Primary Care", speaker Loga K. Regional Seminar of Thessaloniki Medical Society 28 February- 2 March 2020, Volos, Greece.

5. HeGYO round table on Patient Follow Up. Chairmen: Anogianaki A., Efthymiadis K., Kabletsas E. Presentations: "Guidelines for an effective follow up", speaker: Litos I., "The fine balance between effectiveness and toxicity during follow up for early-stage cancer", speaker: Drizou M., "Can modern technology offer more effective follow up?", speaker: Koulouris A. Commentators: Volakakis N., Goumas G., Duran Moreno J., Margari Ch, Rapti K. HeGYO round table during the proceedings of the 25th Hellenic Congress of Medical Oncology, 18-20 April 2019, Athens, Greece.

4. New trends in maintenance therapies. Chairmen: Tsigaridas K., Kokkali S., Efthymiadis K. Presentations: "New data on immunotherapy maintenance", speaker: Loga K., "The value of PARP inhibitors in maintenance therapies", speaker: Sogka E., "The real value of antiangiogenesis maintenance therapy", speaker: Fotarelli A. HeGYO round table during the proceedings of the 10th Medical Oncology Seminar, 2-3 November 2018, Thessaloniki, Greece.

(cont'd)

### **Participation in National Conferences as Chairman/ Commentator (c)**

---

3. End-stage Patient. The gap between life and death. Palliative Care., participation as panel commentator. Commentators: Karvounis N., Lalla E., Mistakidou K., Efthymiadis K., Kokkali S., Zairi E. Palliative Care I: Chairmen: Nasi D., Perdikouri E.I., Kamperis E., presentations: "Pharmaceutic analgesia, right or luxury?", speaker: Zarkavelis G., "Radiotherapy as an analgesic", speaker: Pappas N., "The role of nuclear medicine", speaker: Stamati D. Palliative Care II: Chairmen: Nikolaou M., Theochari M., Andreadou A., presentations: "Holistic care of end-stage patients", speaker: Zarali O., "Hospice and supportive care units", speaker: Kapetanakis G., "The soul and chronic disease", speaker: pr. Theodosios Manolis. HeGYO meeting on "End-Stage Patient. Palliative Care", 3 May 2018, during the proceedings of the 4th Hellenic Congress of Oncology: Passage to the new era, 3-5 May 2018, Thessaloniki, Greece.

2. Spotlight on the shadowy pathways. Chairmen: Efthymiadis K., Samelis G. Presentations: "Endpoints: OS, PFS, RR, QoL. Tools or meat grinder?", speaker: Levva S., "Non- specific disease bombing- chemotherapy: will it remain a therapeutic necessity?", speaker: Magkou E., commentators: Romanidou Ur., Tripodaki E.S., Paraskeva M., Assi A., Rallis G., Litos I. 1st HeGYO & EKEEK scientific meeting, "The spotlights on the shadowy pathways", 10 December 2017, during the congress "From Chemotherapy to Molecular Targeting, Transition in the History of Antineoplastic Therapy", 8-10 December 2017, Athens, Greece.

1. Early breast cancer. Chairmen: Efthymiadis K., Korantzis I. Presentations: "Neoadjuvant therapy in HER2 positive women, which women, in what way?", speaker: Adamidis A., "Genetic signatures in the choice of adjuvant therapy, are there significant differences?", speaker: Adamidis C. HeGYO Meeting "Where oncology meets molecular biology", 19th November 2017 & 9th Medical Oncology Seminar, 17-19 November 2017, Thessaloniki, Greece.

### List of International Conferences Attendance

---

14. ESMO 2022 Congress, 9-13 September 2022, Paris, France.
13. ASCO 2022 Congress, 3-7 June 2022, Online Attendance.
12. ESMO 2021 Congress, 16-21 September 2021, Online Attendance.
11. IASLC 2021 World Conference on Lung Cancer, Worldwide Virtual Event, 8-14 September 2021.
10. ASCO 2021 Annual Meeting, 4-8 June 2021, Online Attendance.
9. IASLC 2019 WCLC World Conference on Lung Cancer, 7-10 September 2019, Barcelona, Spain.
8. ESMO Breast Cancer Congress, 2-4 May 2019, Berlin, Germany.
7. ESMO 2018 Congress, 19-23 October 2018, Munich, Germany.
6. 5th Lung Cancer Network "From the Bench to the Bedside", 18-20 January 2018, Athens, Greece.
5. ESMO 2017 Congress, 8-12 September 2017, Madrid, Spain.
4. 4th Symposium on Thoracic and Upper Aerodigestive Malignancies, 06-09 April 2017, Athens, Greece.
3. 4th Lung Cancer Network "From the Bench to the Bedside", 15-16 January 2016, Athens, Greece.
2. Medichem International Workshop and Mini Symposium: Risk Assessment and Human Exposure to Hazardous materials, 21-24 October 2009, Thessaloniki, Greece.
1. 1st International Symposium on Integrated Research Approaches for Clinical Applications and Practices, 27 February - 2 March 2003, Larissa, Greece.

### List of National Conferences Attendance (a)

---

123. 31st Hellenic Congress of Medical Oncology (HeCMO) "We made time for the things that matter", 9-12 April 2025, Athens, Greece.
122. 4th Panhellenic Congress of Cancer Therapeutics, 27-29 March 2025, Thessaloniki, Greece.
121. Particle Therapy Masterclass, CERN- Conseil Européen pour la Recherche Nucléaire, GSI - Helmholtzzentrum für Schwerionenforschung GmbH, Aristotle University of Thessaloniki, National Center for Scientific Research "Demokritos", 22 February 2025, online.
120. Interdisciplinary collaboration at the Anti-Cancer Hospital. 22-23 November 2024, Thessaloniki, Greece.
119. Innovation in Surgery and Oncology - A European Forum in Greece, European Interbalkan Medical Center, 7-8 November 2024, Thessaloniki, Greece.
118. 16th Postgraduate Seminar of Medical Oncology, 1-2 November 2024, Thessaloniki, Greece.
117. HeSMO Webinar Best of ESMO 2024, 31st October 2024, online.
116. The Optimal Sequencing in the Era of Multiple Therapeutic Options, 20-22 September 2024, Thessaloniki, Greece.
115. 3rd Panhellenic Congress of Cancer Therapeutics, 28-30 March 2024, Thessaloniki, Greece.
114. Particle Therapy Masterclass, Conseil Européen pour la Recherche Nucléaire, GSI - Helmholtzzentrum für Schwerionenforschung GmbH, Aristotle University of Thessaloniki, National Center for Scientific Research "Demokritos", "Papageorgiou" Thessaloniki General Hospital, 23 March 2024, online.
113. British Sarcoma Group Annual Conference, 27-28 February 2024, Leeds, United Kingdom.
112. Symposium with subject: "The appliance of molecular targeted therapies and immunotherapy in solid tumors, 27 January 2024, Thessaloniki, Greece.
111. 15th Postgraduate Seminar of Medical Oncology, 3-4 November 2023, Thessaloniki, Greece
110. Newer data on the Prevention and Treatment of Lung Cancer V, 15-17 September 2023, Thessaloniki, Greece.
109. The Optimal Sequencing in the Era of Multiple Therapeutic Options, 15-16 September 2023, Thessaloniki, Greece.
108. Current topics on respiratory and genitourinary cancer. 1-2 September 2023, Thessaloniki, Greece.
107. Cancer 2023, 26-27 May 2023, Thessaloniki, Greece.
106. 2nd Panhellenic Congress of Cancer Therapeutics, 30 March- 1 April 2023, Thessaloniki, Greece.
105. Particle Therapy Masterclass, Conseil Européen pour la Recherche Nucléaire, GSI - Helmholtzzentrum für Schwerionenforschung GmbH, Aristotle University of Thessaloniki, National Center for Scientific Research "Demokritos", "Papageorgiou" Thessaloniki General Hospital, 4 March 2023, online.
104. Symposium with subject "The appliance of molecular targeted therapies and immunotherapy in solid tumors, 21 January 2023, Thessaloniki, Greece.
103. 14th Postgraduate Seminar of Medical Oncology, 4-5 November 2022, Thessaloniki, Greece.
102. Newer data on the Prevention and Treatment of Lung Cancer IV, 14-16 October 2022, Thessaloniki, Greece.
101. Innovation in Oncology IV, 30 September-2 October 2022, Thessaloniki, Greece.
100. British-Greek Surgical Forum, The UK Surgical Travellers visit to Thessaloniki 2022, 29-30 September 2022, Thessaloniki, Greece.
99. The Optimal Sequencing in the Era of Multiple Therapeutic Options, 16-17 September 2022, Thessaloniki, Greece
98. 1st Congress on Lung Cancer- Form research to clinical practice, 16-18 June 2022, Athens, Greece.
97. Cancer 2022, 27-28 May 2022, Thessaloniki, Greece.
96. 6th Greek Conference of Medical Oncology "Oncology 2022, Citius, Altius, Fortius", 4-7 May 2022, Thessaloniki, Greece.
95. Particle Therapy Masterclass, Conseil Européen pour la Recherche Nucléaire, GSI - Helmholtzzentrum für Schwerionenforschung GmbH, Aristotle University of Thessaloniki, National Center for Scientific Research "Demokritos", "Papageorgiou" Thessaloniki General Hospital, 9 April 2022, online.

94. Panhellenic Congress of Cancer Therapeutics, 31 March- 2 April 2022, Thessaloniki, Greece.  
93. Congress of Clinical and Translational Oncology, 18-21 November 2021, Heraklion, Greece.  
(cont'd)

### List of National Conferences Attendance (b)

---

92. 3rd Northern Greece Oncology Clinical Lessons, 12-14 November 2021, Trikala, Greece.  
91. Scientific Meeting "Current Topics on Gynecological and Urological Cancer", 5-6 November 2021, Thessaloniki, Greece.  
90. Special Topics on Neoadjuvant Treatment. Greek Breast Surgery Society, Webinars Online Seminars, Fall- Winter 2021. 3rd Webinar "Neoadjuvant therapy in breast cancer", 6 November 2021, online.  
89. 13th Postgraduate Seminar of Medical Oncology, 5-6 November 2021, Thessaloniki, Greece.  
88. Educational Seminar: Breast Cancer/ Melanoma 2021, 8-9 October 2021, Thessaloniki, Greece.  
87. Newer data on the Prevention and Treatment of Lung Cancer III, 1-3 October 2021, Thessaloniki, Greece.  
86. 9th Panhellenic Congress of the Research Society of Urogenital Oncology, Thessaloniki, 24-26 September 2021.  
85. The Optimal Sequencing in the Era of Multiple Therapeutic Options, 10-11 September 2021, Thessaloniki, Greece.  
84. HeGYO Symposium "New Journeys in Oncology" as part of the "12th Postgraduate Seminar of Clinical and Research Oncology", 1-3 July 2021, Athens, Greece.  
83. "12th Postgraduate Seminar of Clinical and Research Oncology", 1-3 July 2021, Athens, Greece.  
82. Cancer 2021- Guidelines, 25-27 June 2021, Thessaloniki, Greece.  
81. Web Scientific Event "Urogenital Cancer (prostate, bladder, kidney), Developments in Oncology", 18-19 June 2021, online.  
80. Panhellenic Congress with subject "Current Subjects in Oncology", 27-29 May 2021, Thessaloniki, Greece.  
79. Scientific Meeting for the Management of Lung Cancer: Newer data, 19 May 2021, online.  
78. HeGYO round table, Cancer and fertility preservation, as part of the 27th Greek Conference of Medical Oncology (27th HeSMO)- "Rewriting Oncology, the New Prototype", 13-15 May 2021, Athens, Greece.  
77. 27th Hellenic Conference of Medical Oncology (27th HeCMO)- "Rewriting Oncology, the New Prototype", 13-15 May 2021, Athens, Greece.  
76. Postgraduate Oncology Lessons, 2nd Lesson: Lung Cancer, 6 May 2021, online.  
75. Particle Therapy Masterclass, Conseil Européen pour la Recherche Nucléaire, GSI - Helmholtzzentrum für Schwerionenforschung GmbH, Aristotle University of Thessaloniki, National Center for Scientific Research "Demokritos", "Papageorgiou" Thessaloniki General Hospital, 6 March 2021, online.  
74. Postgraduate Lessons of the Northern Greece Surgical Society, 5th lesson: "Definitive Surgical Treatment of Colon Adenocarcinoma", 10 February 2021, online.  
73. Educational Seminar: Breast Cancer/ Melanoma 2020, 4-5 December 2020, online.  
72. Webinar Cycle "Current Subjects on Oncology: Lung Cancer", 17 November 2020, online.  
71. Congress on Clinical and Translational Oncology, 12-14 November 2020, online.  
70. 35th Northern Greece Medicine Congress, 15-17 October 2020, Thessaloniki, Greece.  
69. Innovation in Oncology II, 2-4 July 2020, Thessaloniki, Greece.  
68. 8th Panhellenic Congress of the Research Society of Urogenital Oncology, 11-13 September 2020, Thessaloniki, Greece.  
67. Cancer 2020- Guidelines, 3-4 July 2020, Thessaloniki, Greece.  
66. Regional Seminar of Thessaloniki Medical Society. 28 February- 2 March 2020, Volos, Greece.  
65. 11th Postgraduate Seminar of Medical and Research Oncology. 20-22 February 2020, Athens, Greece.  
64. Concerns in gynecological malignancies, cancer of the ovaries, uterus and breast. 7-8 February 2020, Thessaloniki, Greece.  
63. 17th Postgraduate Congress, Developments in Oncology, 13-14 December 2019, Rio Greece.  
62. Congress of Medical and Translational Oncology and Congress on Breast Cancer, 14-17 November 2019, Heraklion, Greece.  
61. 39th Panhellenic Congress of Gastroenterology, 10-13 October 2019, Alexandroupoli, Greece.  
60. 7th Panhellenic Congress of the Research Society of Urogenital Oncology, 20-22 September 2019, Thessaloniki, Greece.  
(cont'd)

### List of National Conferences Attendance (c)

---

59. Congress with subject "Optimal sequencing in the era of multiple therapeutic options, 13-15 September 2019, Thessaloniki, Greece.  
58. 4th Scientific Meeting "Oncology on the verge of new developments", 7-9 June 2019, Kastoria, Greece.  
57. 25th Hellenic Congress of Medical Oncology, 18-20 April 2019, Athens, Greece.  
56. Scientific meeting with subject "Unlocking Lung Cancer- Adapting therapy on biology", 16 February 2019, Thessaloniki, Greece.  
55. 10th Medical Oncology Seminar, 2-3 November 2018, Thessaloniki, Greece.  
54. Scientific Meeting "Urogenital Oncology and Primary Care", 21-22 September 2018, Grevena, Greece.  
53. 6th Panhellenic Congress of the Urogenital Oncology Research Society, 14-16 September 2018, Thessaloniki, Greece.

52. Congress with subject: "Current treatment of lung cancer and urogenital cancer (prostate, kidney, bladder)", 22-24 June 2018, Thessaloniki, Greece.
  51. 3rd Scientific Meeting "Oncology on the verge of new developments", 8-10 June 2018, Kastoria, Greece.
  50. Malignant gastrointestinal tumors, Progress and newest data, 11-12 May 2018, Thessaloniki, Greece.
  49. 4th Hellenic Congress of Oncology: Passage to the new era, 3-5th May 2018, Thessaloniki, Greece.
  48. Thessaloniki Medical Association Lessons, Postgraduate Orthopedic Lessons 2018, Musculoskeletal cancer management through Multidisciplinary Tumor Board, 17 April 2018, Thessaloniki, Greece.
  47. 4th Scientific Symposium "Drama against Cancer", 13-15 April 2018, Drama, Greece.
  46. 1st HeGYO & EKEEK scientific meeting, "The spotlights on the shadowy pathways", 10 December 2017, Athens, Greece.
  45. Congress "From Chemotherapy to Molecular Targeting, Transition in the History of Antineoplastic Therapy", 8-10 December 2017, Athens, Greece.
  44. HeGYO Meeting "Where oncology meets molecular biology", 19 November 2017, Thessaloniki, Greece.
  43. 9th Medical Oncology Seminar, 17-19 November 2017, Thessaloniki, Greece.
  42. 5th Panhellenic Congress of the R.S.U.O., Modern Approach of GI and Urological Cancers, 22-24 September 2017, Thessaloniki, Greece.
  41. Oncology Congress with subject: A. Cancer Prevention- Lifestyle- Nutrition- Exercise- Stress, B. Modern approach of Urological Cancer- prostate- urinary bladder- kidney, 30 June- 2 July 2017, Thessaloniki, Greece.
  40. 7th Panhellenic Scientific Meeting of the Urogenital Oncology Department of the Panhellenic Urology Society, 2-4 June 2017, Kavala, Greece.
  39. Annual Meeting on GI Cancers, 16-17 June 2017, Larissa, Greece.
  38. Best of 17th IASLC World Conference on Lung Cancer (WCLC) 2016, 3-4 March 2017, Athens, Greece.
  37. Scientific Meeting "Best of ASCO event in Greece", 23-24 September 2016, Athens, Greece.
  36. 3rd Hellenic Congress of Oncology; 22th Panhellenic Conference of Medical Oncology, 15th Panhellenic Conference of Clinical Oncology, 21-23 April 2016, Ioannina, Greece.
  35. 3rd Scientific Meeting of Northern Greece Urological Oncology, 15-17 April 2016, Thessaloniki, Greece.
  34. 4th Symposium of Medical Oncology, 2-3 April 2016, Rhodes, Greece.
  33. Scientific Meeting on "Prostate Cancer: newest data", 16 March 2016, Thessaloniki, Greece.
  32. 3rd Scientific Symposium «Drama against Cancer»: Prevention and early diagnosis of cancer: from the family doctor to the challenges of modern Biotechnology, 4-6 March 2016, Drama, Greece.
  31. 10th Educational Seminar of Molecular Oncology & Targeted Therapy, 25-27 February 2016, Volos, Greece.
  30. 18th Panhellenic Oncology Congress, 18-21 February 2016, Thessaloniki, Greece.
  29. Best of 16th IASLC World Conference on Lung Cancer (WCLC), 14 January 2016, Athens, Greece.
  28. Scientific Meeting on "Prevention and Therapeutic Approaches of Lung Cancer", 19 December 2015, Kastoria, Greece.
  27. Advances in cancer immunology and immunotherapy, 30-31 October 2015, Athens, Greece.
  26. Scientific Meeting on "Melanoma: newest data", 21 October 2015, Thessaloniki, Greece.
  25. HeGYO Meeting on Acute Oncology, 11 October 2015, Thessaloniki, Greece.
- (cont'd)

### List of National Conferences Attendance (d)

---

24. 8th Medical Oncology Seminar, 09-11 October 2015, Thessaloniki, Greece.
23. 2nd Macedonian Multithematic Oncology Congress, 2-3 October 2015, Kastoria, Greece.
22. Congress of the Hellenic and National Society of Molecular Targeted and Personalized Therapies on "Medical Specialty Coordination for the evaluation and appliance of molecular targeted therapies in solid tumors", 26-27 June 2015, Volos, Greece.
21. 21st Panhellenic Conference of Medical Oncology, 23-25 April 2015, Athens, Greece.
20. 3rd Symposium on Medical Oncology, 28-29 March 2015, Rhodes, Greece.
19. Northern Greece Oncology Congress, 12-14 December 2014, Kalambaka, Greece.
18. 10th Panhellenic Congress of the Hellenic Cardio-Thoracic Surgeons Society & 1st World Meeting of the Hellenic Cardiothoracic Diaspora, 20-22 November 2014, Athens, Greece.
17. Congress on "Urogenital Cancer Guidelines in Greece -How far, how close?", 8-10 November 2014, Athens, Greece.
16. 2nd Symposium on Medical Oncology, 29-30 April 2014, Rhodes, Greece.
15. 2nd Hellenic Congress of Oncology; 20th Panhellenic Conference of Medical Oncology, 13th Panhellenic Conference of Clinical Oncology, 10-12 April 2014, Thessaloniki, Greece.
14. 3rd Oncology Congress of Northern Greece, 10-12 May 2013, Volos, Greece.
13. 19th Panhellenic Conference of Medical Oncology, 13rd Panhellenic Congress of Clinical Oncology, 25-27 April 2013, Athens, Greece.
12. Meeting on Neoplasias of the Reproductive System and Breast in woman, 7-8 December 2012, Athens, Greece.
11. 8th Posteducational Seminar "Breast Cancer from Gene to Therapy", 15-17 November 2012, Thessaloniki, Greece.
10. "Renal Cancer – Prostate Cancer" meeting, 9-10 November 2012, Thessaloniki, Greece.
9. 2nd Psychooncological Meeting, 31 October 2012, Thessaloniki, Greece.
8. 5th Oncology Congress of Central Greece "Lung Cancer- Urogenital Cancer", 24-27 October 2012, Larissa, Greece.
7. 2nd Triple-subject Oncology Congress, 5-7 October 2012, Kastoria, Greece.
6. 1st Annual Meeting of Primary Care and General Practice Trainers, 7 July 2010, Thessaloniki, Greece.
5. 23rd Medical Conference of Northern Greece, 27-29 March 2008, Thessaloniki, Greece.

4. 59th Congress of the Hellenic Society for Biochemistry and Molecular Biology, 7-9 December 2007, Athens, Greece.
3. 57th Congress of the Hellenic Society for Biochemistry and Molecular Biology, 9-11 December 2005, Athens, Greece.
2. 54th Congress of the Hellenic Society for Biochemistry and Molecular Biology, 25-27 October 2002, Ioannina, Greece.
1. 52nd Congress of the Hellenic Society for Biochemistry and Molecular Biology, 24-25 November 2000, Thessaloniki, Greece.